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Resumo 
O péptido beta-amilóide (Aβ) é o principal constituinte das placas 
senis que caracterizam a doença de Alzheimer (DA). O péptido com a 
sequência de 42 aminoácidos é depositado no cérebro extracelularmente, 
o que resulta em morte neuronal. Apesar dos esforços para compreender a 
origem da DA e para encontrar tratamentos eficazes, ainda não existe uma 
cura para esta doença tão debilitante. 
A transição da conformação do péptido Aβ de α-hélice para folhas-β 
leva à sua agregação e parece ser um passo crucial na formação de placas 
senis. A conformação do péptido determina se os agregados tóxicos serão 
formados. Por outro lado, a estrutura do péptido depende do ambiente e 
de interacções entre moléculas. Para compreender as alterações e o 
processo de agregação do péptido é importante realizar estudos de 
interacções do Aβ com diferentes moléculas de tensioactivos. 
O presente trabalho descreve o efeito dos tensioactivos carregados 
e não carregados na fibrilogénese do Aβ(1-42). As interacções péptido–
tensioativo foram caracterizadas através da análise ultra-estrutural, por 
ensaios de tioflavina T e pela análise da estrutura secundária. Estes 
estudos sugerem que os tensioactivos carregados interagem com o Aβ(1-42) 
através de interacções electrostáticas. No caso das micelas carregadas, 
estas tornam o processo de agregação mais lento e estabilizam o péptido 
no estado oligomérico. Por outro lado, os tensioactivos não carregados 
promovem a fibrilogénese do Aβ(1-42). Este estudo contribui para 
 
 
 
iv 
 
compreender a agregação de péptidos e selecionar moléculas que sejam 
potenciais inibidores da agregação do péptido Aβ(1-42). 
Três novos péptidos foram concebidos e testados como inibidores 
da agregação do Aβ(1-42). As sequências são baseadas nos resíduos 
hidrofóbicos do Aβ(1-42) (resíduos de 17-21) e no péptido inibidor LPFFD 
(iAβ5). Devido às vantagens que as moléculas fluoradas têm em medicina, 
foram adicionados átomos de flúor às sequências. Com o objetivo de 
aumentar a biodisponibilidade e a solubilidade destes péptidos, uma 
molécula de poli(etileno-glicol) (PEG) foi ligada covalentemente no 
terminal-C de cada péptido. Os péptidos fluorados conjugados foram 
caracterizados por ionização e dessorção a laser assistida por matriz e a 
cinética de agregação do Aβ(1-42) na sua presença foi analisada através 
do ensaio de tioflavina T. Para além disso, a morfologia dos agregados foi 
observada por microscopia electrónica de transmissão. Os estudos 
demonstram que duas sequências de péptidos fluorados conjugados 
(LVFfFD-PEG e LVfFFD-PEG) inibem a agregação do péptido Aβ(1-42) a 
baixas concentrações. 
Fármacos promissores para o tratamento da DA podem nunca vir a 
ser utilizados devido à sua inaptidão em chegar ao cérebro em 
concentrações desejadas dado à existência da barreira hemato-encefálica. 
Para contornar este problema, foram concebidos e testados lipossomas 
peguilados funcionalizados com dois tipos de anticorpos: um que 
reconhece o receptor de transferrina (OX -26) e outro que reconhece o 
péptido beta amilóide (19B8). Estudos in vivo em ratos demonstraram que 
a concentração dos imunolipossomas é substancialmente mais elevada nos 
tecidos cerebrais do que a dos lipossomas não-funcionalizados. Este 
sistema foi utilizado para encapsular o inibidor LPFFD, demonstrando 
assim a sua aplicação como transportador de fármacos para o tratamento 
da DA. 
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Abstract 
Amyloid-beta peptide (Aβ) is the major constituent of Alzheimer’s 
disease (AD) plaques. The peptide, with a sequence of 42 amino acids, 
deposits in the brain extracellularly, which results in neuronal loss. 
Despite the efforts to understand the etiology of AD and to find effective 
treatments, there is still no cure for such debilitating disease. 
The α-helix to β-sheet transition of Aβ peptide conformation leads 
to its aggregation and seems to be the crucial step of the formation of 
neuritic plaques. The peptide conformation determines if toxic aggregates 
will be formed. On the other hand, the peptide structure depends on the 
environment and molecule–molecule interactions. In order to understand 
the alterations and the aggregation process of the peptide, it is important 
to perform studies of Aβ interactions with different surfactant molecules.   
The present work describes the effect of charged and non-charged 
surfactants on Aβ(1-42) fibrillization. The characterization of the peptide-
surfactant interactions by ultra-structural analysis, thioflavin T (ThT) 
assay and secondary structure analysis suggests that charged surfactants 
interact with Aβ(1-42) through electrostatic interactions. Charged micelles 
slow down the aggregation process and stabilize the peptide in the 
oligomeric state, whereas non-charged surfactants promote the Aβ(1-42) 
fibril formation. This study contributes to better understand the peptide 
aggregation and screen for molecules that can inhibit amyloid fibril 
formation.  
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Three new peptides were designed and tested as inhibitors of Aβ 
aggregation. The sequences are based on the hydrophobic central residues 
of Aβ(1-42) (17-21) and on the beta-sheet breaker peptide LPFFD (iAβ5). 
Due to the benefits of fluorine in medicine, fluorine atoms were added to 
the sequences. For the purpose of increasing the bioavailability and 
solubility of these peptides, poly(ethylene glycol) (PEG) was covalently 
linked at their C-terminal. The fluorinated peptide conjugates were 
characterized by MALDI-TOF and the aggregation kinetic of Aβ(1-42) in their 
presence was monitored by ThT assay. Furthermore, the morphology of 
the aggregates was analysed by transmission electron microscopy. The 
studies demonstrate that two sequences conjugated to PEG (LVFfFD-PEG 
and LVfFFD-PEG) inhibit the aggregation of Aβ(1-42) peptide, at low molar 
ratios. 
 Potential drugs for the treatment of AD may not be able to access 
the brain at desired concentrations due to the blood brain barrier. To 
circumvent this problem, a novel carrier-based on pegylated liposomes 
functionalized with transferrin receptor antibody (OX-26) and anti-Aβ 
peptide (19B8) was prepared. In vivo studies in rats showed that the 
uptake of the immunoliposomes was substantially higher when compared 
to non-functionalized liposomes. This system was used to encapsulate a 
beta-sheet breaker peptide, demonstrating its application as a drug carrier 
for the treatment of AD.   
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CHAPTER 1  
1. Introduction 
Alzheimer’s disease (AD) is characterized by an alteration of the 
structure of the proteins amyloid-beta and Tau protein and their 
subsequent aggregation. The aggregates deposit in the brain, 
extracellularly (amyloid-beta) or appear inside the cells (aggregates of 
hyperphosphorylated Tau protein) resulting in neuronal loss (Hardy, 
2002).  Several evidences from genetic and animal models have 
established a causative role of the amyloid beta-peptide (Aβ) in the onset 
of the disease (Hardy, 1992). The most abundant forms of Aβ peptide have 
40 (~90%) and 42 (~10%) amino acids (a.a.) (Barrow, 1991). The shorter 
peptide, with 40 a.a., is found mainly in cerebrovascular amyloid deposits 
and the sequence of 42 residues is the major component of the amyloid 
plaque core. 
Physiological Aβ in monomeric form is benign, but by an unknown 
mechanism it aggregates and becomes neurotoxic (Lorenzo, 1994). 
Initially, Aβ monomers are converted into soluble aggregates called 
oligomers that have a β-sheet structure. Oligomers will then aggregate 
further and form protofibrils. The aggregation of these protofibrils 
originates insoluble fibrils. The conversion of oligomers into fibrils may 
result from a transition of antiparallel to parallel β-sheet. In the brains of 
AD patients, the peptide is found in a fibrillar form organized in a β-sheet 
structure (Sarroukh, 2011). 
The formation of Aβ soluble oligomers may be the critical factor in the 
development of AD rather than the insoluble fibrils. It was suggested that 
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these oligomeric structures induce toxicity through a mechanism related 
to the folded structure rather than their sequence (Bucciantini, 2002). 
Further evidence of toxic structures was obtained when antibodies 
specific to Aβ oligomers were shown to inhibit the toxicity not only of Aβ 
oligomers but also of several other protein oligomers (Kayed, 2003).  
The steady state levels of Aβ in the brain are controlled by 3 factors (i) 
production; (ii) degradation and (iii) aggregation, which is a concentration 
dependent process. A plausible therapeutic strategy is to inhibit and 
reverse the peptide aggregation, because this appears to be the first step 
in the AD pathogenic process not associated with natural biological 
functions. 
As several findings suggest that a conformational transition from 
random coil/α-helix structure to β-sheets is responsible for Aβ 
aggregation (Yang, 2008), a strategy to prevent this process could be the 
reconversion of Aβ conformation. This reconversion can be promoted by 
the addition of a compound that is able to remove the beta conformation 
out of the equilibrium (Levine, 2007).  Until now, a range of small 
molecules was found to inhibit and reduce the aggregation of Aβ (Mason, 
2003).  
Fluoroorganic compounds are molecules with a lot of interest for 
medical applications due to the unique properties of the fluorine atom 
(Bohm, 2004). Fluorine is quite often introduced to improve the metabolic 
stability and to modulate the physicochemical properties such as 
lipophilicity or basicity of molecules. Few fluorinated compounds have 
been studied in regard to protein misfolding (Giacomelli, 2005). 
Organofluorine compounds were proven to be effective inhibitors of Aβ(1-
40) fibrillogenesis (Torok, 2006). Also, complexes made of polyampholyte 
and the sodium salt of perfluorododecanoic acid induce α-helix rich 
structures in Aβ and prevent fibril formation, whereas the hydrogenated 
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analogues were not efficient, leading to β-sheet formation and aggregation 
(Saraiva, 2010). 
Despite the knowledge already obtained about AD, most clinical trials 
of promising drugs for the treatment of this disease have failed. Most of 
these failures are due to the inability of drugs to cross the blood-brain 
barrier (BBB). Aproximately 100% of large-molecule drugs and 98% of 
small-molecule drugs do not cross the BBB (Pardridge, 2003). Only small 
molecules with high lipid solubility and low molecular mass of < 400–500 
Daltons can effectively cross the BBB (Pardridge, 2003).  However there 
are only a few brain diseases that consistently respond to this category of 
small molecules (Ajay, 1999).  
 
The main objectives with the work presented in this thesis are: 
- to better understand the interaction of Aβ peptide with charged 
and nonionic amphiphiles/micelles; 
- to develop fluorinated peptides and conjugates as inhibitors of Aβ 
assembly; 
- to design liposomal carriers as effective vehicles of fluorinated 
peptides and conjugates able to cross the BBB. 
This thesis is organised into six chapters. This chapter, 
“Introduction”, covers the objectives and scope of the research work. 
Chapter 2, “State of the art”, contains an overview of the Aβ peptide and 
AD, the beta-sheet breaker peptides already developed, including their 
efficiency in inhibiting the peptide aggregation, the function of the BBB 
and drug delivery systems that target Aβ. Chapter 3, “Interaction of Aβ 
peptide with charged and nonionic surfactants”, presents and discusses 
the interaction study of Aβ(1-40) and Aβ(1-42) with ionic and nonionic 
surfactants. Chapter 4, “Effect of fluorinated peptides on Aβ assembly”, is 
dedicated to the design and characterization of sequences of five a.a. 
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including a fluorinated residue with the aim of inhibiting the Aβ 
aggregation. The chapter 5, “Design of liposomes coupled to monoclonal 
antibodies to cross the blood-brain barrier”, describes the methodology 
involved in the preparation and characterization of the liposomes and 
their study in vitro and in vivo. Chapter 6, “Concluding remarks”, 
summarizes the main findings of this research work. 
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 CHAPTER 2 
2. State of the art 
2.1. Introduction 
AD affects more than 35 million people and it is considered the 
most common form of dementia worldwide. By 2050, the prevalence is 
estimated to quadruple (Brookmeyer, 2007). The initial symptoms of AD 
are practically imperceptible and characteristically involve lapses of 
memory for recent events (Forstl, 1999). In addition, the performance for 
complex tasks and ability to acquire new information can be reduced. 
After a couple of years the patients lose the cognitive functions and show 
spatial disorientation, apathy, general disinterest and difficulty in 
performing simple tasks such as preparing meals.  Commonly an 
emotional control loss is observed in patients with AD, a symptom that 
may be accompanied by physical or verbal aggression. With the evolution 
of the disease, people develop motor problems and present difficulty for 
walking and for simple activities like dress up. Over the time, the disease 
causes a progressive decline of the patient life with intense memory and 
cognition losses, leading to the immobility of the patients that succumb to 
respiratory difficulties. Normally, this disorder appears among people 
over the age of 65 years, with an average of eight year living after the 
appearance of the first symptoms (Larson, 2004). The impact of AD on the 
health care systems is also a very pronounced problem in developed 
countries. Considering the increase in population aging and survival, the 
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economic effects caused by this disease are expected. Therefore, strategies 
for its early detection and treatment are an ambitious challenge in modern 
medicine.  
Two pathophysiological hallmarks in the brain characterize this 
neuropathological disease: intracellular neurofibrillar tangles of 
hyperphosphorylated tau protein and extracellular accumulation of Aβ 
peptide (senile plaques) (Calhoun, 1999; Clippingdale, 2001; Hardy, 
2002a). The peptide is aggregated as amyloid fibrils within the neuritic 
plaques and vascular deposits (Kirschner, 1986; Selkoe, 2001). Scientific 
evidences from genetic and animal models have established a causative 
role of Aβ in AD (Hardy, 2002b; Hardy, 1992). The existing treatments 
only attenuate the symptoms of the disease and, at the present, no 
therapies have been clinically proven to effectively prevent the 
progression of AD. 
Different factors limit the development of new medicines. Short 
drugs do not circulate more than some instants in the blood stream, 
because they suffer enzymatic degradation (J.L. Fauchere, 1992). Other 
limiting factor is the poor ability of the drugs to cross the BBB and reach 
the central nervous system (CNS). Although nanotechnology is expected to 
have a huge impact on the development of “smart” drug delivery devices 
against AD, a crucial gap still needs to be filled (Brambilla, 2011). Several 
types of biologically active molecules are being encapsulated into 
nanoparticles (NPs) for their delivery to the brain. Liposomes are one of 
the most studied vehicles to transport drugs toward the site of action and 
several improvements were achieved during the last decades (Lai, 2013). 
The selectivity of these carriers could be improved with ligands attached 
at their surfaces. Monoclonal antibodies (mAb) are probably the most 
efficient ligands to target NPs (Liu, 2010). This improvement increases the 
efficiency of the treatments and decreases the undesirable side effects of 
the drugs. 
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2.2. Amyloid beta-peptide and 
Alzheimer’s disease 
Evidences support a direct association between the degree of 
dementia of patients that have AD and the concentration of soluble 
aggregates of the Aβ peptide (Clippingdale, 2001; Hardy, 2002a; Ladiwala, 
2012). The Aβ peptide derives from the amyloid precursor protein (APP) 
by sequential activities of β- and γ-secretases (Haass, 1993; Kang, 1987; 
Weidemann, 1989), a process explained by a theory that was formulated 
20 years ago: the cascade hypothesis (Hardy, 1992). This hypothesis has 
been the most influential in the AD research conducted by the academia 
and in the pharmaceutical industry. 
 
 
2.2.1. Amyloid cascade hypothesis 
Originally, when the amyloid cascade hypothesis was presented, 
the Aβ peptides and their aggregated forms were suggested to be 
responsible for initiating cellular events leading to the pathologic effects of 
AD. According to the first version of the amyloid cascade hypothesis, Aβ 
fibrils deposited in amyloid plaques were thought to cause neuronal 
dysfunction (Hardy, 1992; Selkoe, 1991). Recently, studies support that 
diffusable Aβ oligomers including protofibrils and prefibrillar aggregates, 
are the major toxic species during the disease development and 
progression (Haass, 2007; Shankar, 2007; Shankar, 2008).  
The transmembrane APP is an integral membrane protein with a 
single membrane-spanning domain, a large extracellular  glycosylated N-
terminus and a shorter cytoplasmic C-terminus, that is expressed in many 
tissues and concentrated in the synapses of neurons. APP is produced in 
several different isomers ranging in size from 695 to 770 a.a.. The shorter 
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sequence is the most abundant form in the brain (Mattson, 1997). This 
protein can be processed along two main pathways: non-amyloidogenic 
and amyloidogenic. In the non-amyloidogenic pathway, APP is cleaved in 
its transmembrane region by the α-secretase, a proteolytic enzyme. This 
cleavage leads to the formation of a soluble APP fragment (sAPPα) and a 
C83 carboxy-terminal fragment. During the amyloidogenic pathway, Aβ is 
obtained by the cleavage of APP through the sequential actions of β- and γ-
secretases. The γ-secretase cleaves the APP in the transmembrane region, 
produces the C-terminal end in the Aβ peptide, generating Aβ peptides 
ranging in length from 38 to 43 residues (Selkoe, 2007) (Figure 2.1). The 
most abundant isoforms are Aβ(1-40) and Aβ(1-42). The Aβ(1-42) is 
characteristically produced by cleavage that occurs in the endoplasmic 
reticulum, while the Aβ(1-40) is produced by cleavage in the trans-Golgi 
network (Hartmann, 1997). After its production, Aβ may aggregate into 
oligomers, fibrils and finally in neurotoxic amyloid plaques by an unknown 
mechanism. In addition, apolipoprotein E (ApoE) gene represents the 
major genetic risk factor for the disease (Strittmatter, 1993). The ApoE can 
act as a chaperone of Aβ, promoting the conformational transformation 
from soluble Aβ into toxic aggregates. The formation of toxic aggregates 
induces an inflammatory response and a situation of oxidative stress, 
which consequently causes the neuronal loss characteristic of AD (Sun, 
2012).  
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Figure 2.1 – Amyloid cascade hypothesis 
 
2.2.2. Amyloid beta peptide 
As mentioned before, Aβ is a metabolic product of an enzymatic 
process from a transmembranar protein, the APP. This enzymatic set of 
reactions has as final products, two principal sequences with a length of 
40 or 42 a.a. (Kang, 1987). The sequence of 40 residues is normally 
produced more abundantly by cells (concentration of secreted Aβ(1-42) is 
10-fold lower that of Aβ(1-40)) and its aggregation kinetic rate is much 
lower than that of the 42 (Aβ(1-40) at 20 µM is stable for 8 days or more 
whereas Aβ(1-42) aggregates immediately) (Haass, 1992; Jarrett, 1993a). 
However, Aβ(1-42) is the most fibrillogenic sequence and is thus associated 
with disease states. The ratio Aβ(1-42)/Aβ(1-40) has been related to the 
progression of AD as its increase is associated to the aggregation of Aβ(1-42) 
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and consequently neurotoxicity (Haass, 2007). The aggregation process of 
the Aβ peptide leads to the formation of insoluble fibrils, which 
accumulate in senile plaques, deposits that characterize AD (Andreasen, 
2002; Suh, 2002). In this state Aβ is in a β-sheet conformation. The smaller 
aggregated intermediates, the Aβ oligomers, are considered one of the 
more toxic species (Hardy, 2002a). The control of Aβ oligomerization is 
difficult to achieve, because the process is fast and is affected by many 
variables (Stine, 2003).  Aβ(1-40) monomers inhibit the aggregation of Aβ(1-
42)/Aβ(1-40) mixtures (in a concentration-dependent manner), whereas 
Aβ(1-42) fibrils accelerate their fibrillogenesis (Jan, 2008; Kuperstein, 
2010). The Aβ(1-42) also affects the aggregation of the mixture by 
accelerating the process. The factors that lead to the in vivo aggregation of 
amyloid peptides can be numerous and are difficult to identify. An 
important feature is the conformation of soluble oligomers (smaller 
intermediates in the aggregation process) which is common for several 
different amyloid-prone synthetic proteins (Kayed, 2003). 
This aggregation process has a nucleation-dependent mechanism in 
which partially folded forms of the peptide associate to form a stable 
nucleus (Jahn, 2005; Merlini, 2003). This nucleus acts as a template to 
sequester other intermediates to add to the growing thread of aggregated 
peptide forming the protofibrils. The consecutive addition of partially 
folded intermediates to the ends of the chain leads to the formation of a 
highly structured and insoluble amyloid fibrils. The time course of the 
conversion of the peptide into fibrils typically includes three phases: lag 
phase, elongation phase and plateau phase. In the first phase, the lag 
phase, the unfolding of Aβ and the formation of oligomers occur, which 
include β-sheet-rich species that act as nuclei for the formation of mature 
fibrils. In the elongation phase, once a nucleus is formed, the fibril growth 
is thought to proceed by the exponentially addition of monomers or 
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oligomers to the growing nucleus. In the last phase, the plateau phase, the 
maximum fibril growth is reached (Figure 2.2). 
 
 
Figure 2.2 – Representation of the Aβ peptide aggregation process. 
 
2.3. Beta-sheet breaker peptides 
Peripheral treatment of AD with molecules that do not cross the 
BBB but have a high affinity for Aβ can reduce the level of the peptide in 
the brain through the sink effect (Brambilla, 2011). The inhibition of Aβ 
aggregation is an attractive therapeutic strategy because this is the first 
step in the pathogenic process of amyloidosis. Until now, several groups 
developed different chemical compounds that inhibit Aβ aggregation or 
promote the disaggregation of the already formed fibrils (Esler, 1997; 
  
 
14 Chapter 2 
 
Kisilevsky, 1995; Merlini, 1995; Wood, 1996). There are several examples 
of molecules with these properties: β-cyclodextrin, hemin and related 
porphyrins, anthracycline 4’-iodo-4’-deoxydoxorubicin, hexadecyl-n-
methylpiperidinium bromide, rifampicin, (-)-5,8-dihydroxy-3r-methyl-2r-
(dipropylamino)-1,2,3,4-tetrahydronapthalene and melatonin (a hormone 
that crosses the BBB and can block Aβ fibril formation) (Mason, 2003; 
Pappolla, 1998; Schwarzman, 2005). Also, it was demonstrated that 
natural occurring inositol stereoisomers stabilized the small Aβ 
aggregates (McLaurin, 2000). Nevertheless, most of small molecules tested 
are weekly potent and poorly bioavailable, particularly to the brain. 
In parallel with these traditional small molecule drugs, an attractive 
strategy is the use of therapeutic peptides (linear molecules with two or 
more a.a. residues, but less than 100) because of their high biological 
activity associated with low toxicity and high specificity (Funke, 2012). 
These therapeutic peptides have many advantages including little 
unspecific binding to molecular structures other than the desired target, 
minimization of drug-drug interactions and negligible accumulation in 
tissues, reducing risks of complications due to metabolic products (Sun, 
2012). Today, around 70 therapeutic peptides to treat different types of 
diseases are on the market, 150 in clinical phases and more than 400 in 
the pre-clinics (Funke, 2012). 
Considerable progress has already been made in discovering 
inhibitors of Aβ aggregation and a range of peptides, which block amyloid 
formation, were developed for therapeutic purposes (Findeis, 2000; 
Findeis, 1999; Hughes, 1996; Soto, 1998; Tjernberg, 1996). Mostly, the 
inhibitors are focused on the internal Aβ sequence 16-22, KLVFFAE, 
because this region has been reported to be primarily responsible for the 
self-association and aggregation of the peptide (Tjernberg, 1997; 
Tjernberg, 1996). The starting point of modified peptide aggregation 
inhibitors was the Aβ(16-20) (KLVFF) peptide which can bind to the full-
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length Aβ and prevent the formation of fibrils (Tjernberg, 1997; Tjernberg, 
1996). Based on this peptide, Soto et al. designed an 11 a.a. peptide, iAβ1 
(RDLPFFPVPID), which binds to Aβ and inhibits Aβ aggregation in vitro 
(Soto, 1996). They designed also a shorter peptide, iAβ5 (LPFFD), that 
presented a similar inhibitory effect to the 11 residue sequence but 
improved BBB permeability due to the reduced molecular mass (Soto, 
1996). LPFFD is based on one of the two hydrophobic zones of Aβ peptide 
responsible for the aggregation, residues 17-21 (LVFFA) (Hilbich, 1992; 
Jarrett, 1993b; Soto, 1996). This inhibitor has a similar degree of 
hydrophobicity, but has a very low propensity to adopt a β-sheet 
conformation due to the proline residue (Soto, 1996). In order to block the 
oligomerization, the LVFFA sequence was modified. The a.a. valine, which 
is considered a key residue for β-sheet formation, was replaced by an a.a. 
thermodynamically unable to fit in the β-sheet structure, the proline (P), 
and the a.a. alanine was replaced by aspartic acid (D) to increase the 
solubility (Chou, 1978; Soto, 1996; Wood, 1995). The peptide LPFFD binds 
to Aβ(1-42) and blocks the interaction between monomers and oligomers 
and therefore the formation of the oligomeric β-sheet conformation 
precursor of the fibrils. However, the peptides generally show poor 
bioavailability both in tissues and organs, preventing their usefulness as 
therapeutic agents. Short peptides usually do not circulate more than a 
few minutes in blood stream and therefore they cannot reach their site of 
action (J.L. Fauchere, 1992). To prevent the enzymatic degradation in the 
blood stream, Rocha et al. coupled the iAβ5 to PEG to increase their 
molecular weight, reduce their immunogenicity and, consequently, 
prolong their half-life in vivo (Rocha, 2009). The pegylation of iAβ5 did not 
affect its activity (Rocha, 2009). PEG has very low toxicity and it is known 
to mask the protein, reducing its degradation by proteolytic enzymes  
(Veronese, 2001). This is an exceptional advantage for the preparation of 
peptide conjugates. Other peptide sequences were developed with the 
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same objective of preventing the Aβ aggregation, nevertheless only very 
few were shown to be effective in rodent AD models or in clinical trials 
(Table 2.1) (Funke, 2012).  
 
Table 2.1 - The AD therapeutic sequences that were shown to be effective in 
rodent AD models or in clinical studies. 
Name Sequence Description Ref. 
iAβ11 RDLPFFPVPID Aβ based  
β-sheet breaker 
(Soto, 1996) 
iAβ5 LPFFD (Soto, 1998) 
PPI-1019
*
 Metyl-LVFFL 
iAβ5 derivatives 
to improve the 
pharmaceutical 
properties 
(Findeis, 2002) 
Ac-iAβ5-amid Ac- LPFFD-amid 
(Chacon, 2004; 
Permanne, 2002) 
LPYFDa LPYFDamid 
(Datki, 2004; 
Juhasz, 2009; 
Szegedi, 2005) 
NH2-D-Trp-Aib-OH Ac-Trp-Aib Dipeptide β-sheet breaker 
(Frydman-
Marom, 2009) 
*Completed phase II clinical trial 
 
Another promising amyloid-inhibitor is the OR1, with the a.a. 
sequence RGKLVFFGR. This peptide was designed based on the central 
region of Aβ, KLVFF  (residues 16-20), which as mentioned above, is part 
of the binding region responsible for its aggregation (Tjernberg, 1996). the 
cationic a.a. arginine was added at  N- and C-termini of the sequence, using 
a glycine as a spacer, to improve the solubility of the inhibitor and prevent 
its self-aggregation and thus its action as a “seed” that would promote Aβ 
aggregation, (Austen, 2008). Also, the introduction of the glycine residues 
as spacers simplify the interaction between the inhibitor peptides and Aβ 
(Austen, 2008). The addition of the -NH2 group at the end of the sequence 
OR1, RGKLVFFGR-NH2 (named OR2), increases the inhibitor effect in the 
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Aβ aggregation (Tjernberg, 1997). On the other hand, OR2 presents 
several potential sites for proteolytic cleavage. To solve this problem a 
“retro-inverso” peptide that maintains the inhibitor effect and blocks the 
proteolytic degradation was designed (RI-OR2) (Matharu, 2010). 
Additionally, a possible strategy to prevent enzymatic cleavage is to 
use N-methylated peptides that bind to Aβ through one hydrogen-bonding 
face while blocking the propagation of the hydrogen bond array of the β-
sheet with the other non-hydrogen-bonding face (Gordon, 2001; Kokkoni, 
2006). 
 
2.4. The importance of fluorine in 
medical chemistry 
Compounds that contains fluorine atoms are of exceptional interest 
for medical applications due to the unique properties of these atoms 
(Torok, 2006). The substitution of various chemical groups by fluorine has 
played and continues to play an important role in the development of 
more active, efficient and selective agents (Kirk, 2006).  
As predictable from its place on the periodic table of chemical 
elements, fluorine possesses high electronegativity in comparison with 
other halogens and presents a small atomic radius among these elements 
(Smart, 2001). The advantages to design drugs with fluorine atom include 
the small size, the specific effects that enhance binding to target 
macromolecules and the high electronegativity. This last benefit has been 
used in many ways to develop enzyme inhibitors or to render molecule 
resistant to chemical degradation (Kirsch, 2004; Ojima, 1996; Soloshonok, 
1999). Other beneficial property of the fluorine substitution is the increase 
of BBB permeability due to changes in the lipophilicity or amine pKa that 
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are of high interest in the design of CNS active drugs (Filler, 1982; Kirsch, 
2004; Malamas, 2010). 
Recent studies suggest that the C–F bond (van der Waals radius = 
1.5 Å) is greater than the C–H bond (van der Waals radius = 1.2 Å), thus 
the substitution of hydrogen by fluorine is regarded as a bioisosteric way 
of introducing strong electron-withdrawing properties into molecules 
(Banks, 1994; O'Hagan, 2008). The importance of fluorine in medicinal 
chemistry is well recognized and the number of drugs on the market that 
contain fluorine are increasing (Kirk, 2006). 
Over the past decade a steady stream of fluorinated drugs brought 
significant advances into drug development for the treatment of different 
diseases, for example, diseases of the CNS, various cardiovascular diseases, 
obesity, and it was also used as antibacterial agents as it is the case of the 
fluoroquinolone and antifungal like fluoroazole (Kirk, 2006; Kirsch, 2004; 
Ojima, 1996; Soloshonok, 1999). Fluorine has played a particularly 
important and historical role in the development of antipsychotic drugs, 
also called neuroleptics or major tranquilizers. These agents are used in 
the treatment of schizophrenia, mania and psychotic depression (Granger, 
2005; Rowley, 2001). 
Small organic molecules are known to efficiently regulate protein-
protein interactions and are proposed to be good candidates to interfere 
with the aggregation of Aβ (Berg, 2003; Iversen, 2002). In order to inhibit 
the protein misfolding, compounds with fluorine atoms have been studied  
(Makhaeva, 2009). Adsorption studies of Aβ monomers and small 
oligomers on poly(tetrafluoroethylene) surfaces have shown that the 
fluorinated surface promotes α-helix re-formation (Giacomelli, 2003). A 
comparable effect was verified when Aβ was in contact with a CF3-group-
containing solvents (2,2,2-trifluoroethanol, 1,1,1,3,3,3-hexafluoro-2-
propanol) (Vieira, 2003). On the other hand, ethanol and 2-propanol have 
showed only reasonable stabilizing effects at high concentrations (75% 
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concentration, 26% α-helix). The fluorinated derivatives are significantly 
more effective as stabilizers at lower concentrations (10% concentration, 
48% α-helix). Also, Torok et al, demonstrate an exceptional efficacy of a 
new class of organofluorine inhibitors on the inhibition of the in vitro self-
assembly of Aβ(1-40) peptide (Torok, 2006). Sood and co-workers have 
observed that 5’-halogen substituted 3,3,3-trifluoromethyl-2-hydroxyl-
(indol-3-yl)-propionic acid esters showed significant activity in the 
disassembly of preformed fibrils making them candidates for further drug 
development (Sood, 2011). 
Aminoisoindoles have also been evaluated as inhibitors of the β-site 
amyloid precursor protein cleaving enzyme 1 (BACE1). The introduction 
of fluorine adjacent to the amidine moiety, besides improving the 
permeability properties in the brain, it resulted in in vivo brain reduction 
of Aβ(1-40) (Swahn, 2012). Also, novel polyhydroxylated (E)-stilbenes were 
synthesized with the objective of inhibiting the enzymes acetyl- and 
butyrylcholinesterase and one of them carrying an extra fluorine 
substituent presented a very stronger action when compared with other 
known inhibitors (Csuk, 2013). 
2.5. Blood-brain barrier 
The exchange of molecules between the blood and brain 
parenchyma is regulated by three main barriers: the BBB formed by glial 
cells and endothelial cells of the blood vessels in the brain; the choroid 
plexus epithelium, which is the border between the blood and ventricular 
cerebrospinal fluid; and the arachnoid epithelium, which separates the 
blood from the subarachnoid cerebrospinal fluid (Pedro Ramos-Cabrer, 
2013). The BBB is formed by the endothelial cell layer, which constitutes 
the capillary, followed by a basement membrane where pericytes and 
astrocytic feet processes lie (Alam, 2010; Egleton, 1997). These cells are 
responsible for several functions like maintenance of neuronal 
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microenvironment, tissue homeostasis, vasotonous regulation, 
fibrinolysis, coagulation, blood cell activation or migration during 
physiological and pathological processes. The barrier also helps in the 
vascularisation of normal neoplastic tissues (Alam, 2010; Risau, 1995), 
even though the main role of the cerebral membrane is to protect the CNS 
from foreign substances (Huang, 2013; Pardridge, 2007). This protection 
is achieved due to the capillary bed of the brain, which was found to differ 
from peripheral capillary beds mainly in the following features: i) the 
intercellular spaces between adjacent capillaries are reduced by tight 
junctions; ii) pinocytosis is significantly decreased; iii) fenestrations and 
other intracellular leaks are essentially absent (Banks, 2008). The 
presence of the tight junctions between the endothelial cells at the BBB 
promotes a very high electrical resistance of around 1500–2000 Ω.cm2 in 
the brain (Crone, 1982) as compared to 3.33 Ω.cm2 in other body tissues 
(Crone, 1981). Endothelial cells also contain large concentrations of P-
glycoprotein (P-gp), an adenosine triphosphate (ATP) dependent protein 
that actively transports a wide range of molecules out of the brain, by an 
efflux pump (Begley, 1996; Bernacki, 2008; Wohlfart, 2012). 
Most molecules are forced to cross the BBB via the transcellular 
route due to the tight junction between adjacent endothelial cells. Only 
small lipophilic molecules, with less than 400 Da, are able to cross the BBB 
by simple diffusion (Figure 2.3) (Boado, 2011; Pardridge, 2002). The BBB 
is not a passive, anatomical lipid phase membrane, but rather a dynamic 
interface containing both physical and metabolic transporter components 
(Fricker, 2004). Different endogenous transport systems are expressed at 
the BBB surface and are responsible for the transport of essential 
hydrophilic molecules/macromolecules to the brain. Molecules such as 
glucose or a.a. are transported through membrane proteins (Figure 2.1). 
Hydrophilic essential macromolecules such as proteins are transferred by 
endocytosis in vesicles, which can be either specific (receptor-mediated 
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transcytosis) or less specific (adsorptive-mediated transcytosis) (Figure 
2.3). Some large molecules such as transferrin and insulin are transported 
via the receptor mediated transport (RMT) which is the transport through 
specialized ligand-specific receptor systems expressed at the surface of the 
brain endothelial cells (Alam, 2010). The receptors that are more 
abundantly expressed by the BBB endothelial cells are the transferrin and 
the insulin receptors (Boado, 2007; Jefferies, 1984; Wohlfart, 2012). 
Adsorptive endocytosis occurs with plasmatic proteins such as albumin in 
which the transport is triggered by the electrostatic interactions between 
the positively charged proteins and negatively charged regions of the 
membrane surface of brain endothelial cells (Pedro Ramos-Cabrer, 2013). 
 
Figure 2.3 - Mechanisms of transport of substances across the BBB: 1- 
paracellular aqueous pathway used by water soluble agents; 2- transport of 
lipophilic molecules by transcellular pathway; 3-transport through 
membrane proteins used by glucose or a.a.; 4- receptor mediated 
transcytosis of macromolecules (e.g. insulin, transferrin); 5-Adsorptive 
transcytosis of cationized plasmatic proteins. 
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2.6. Drug delivery systems to cross the 
blood brain barrier 
The therapy of CNS diseases is hampered by the low bioavailability 
of drugs and their rapid degradation in the blood. Colloidal systems have 
the potential of transporting drugs that normally would not cross the BBB 
to the brain by masking their physicochemical characteristics through 
encapsulation (Andrieux, 2009). Several NPs have been developed to 
protect and transport the desired molecules into the brain. NPs can be 
classified in either reversible or irreversible complexes. The reversible 
NPs are supramolecular complexes formed by noncovalent intermolecular 
interactions as van der Waals forces or lipophilic interactions. Liposomes 
are the best known example of this type of nanoparticle (Pedro Ramos-
Cabrer, 2013). Non-reversible NPs (including dendrimers, nanocapsules, 
nanospheres, nanocages, and nanotubes) comprise molecules with strong 
molecular interactions like covalent or metallic bonds, which confer a high 
degree of stability (Alam, 2010; Pedro Ramos-Cabrer, 2013). A major 
problem of the nanocarriers is their low cell specificity (Banks, 2008). In 
addition, they need to be optimized for each specific drug to lead to its 
efficient and controlled delivery. For example, the molecular weight of 
polymers used to prepare NPs can be modulated for controlling the 
release mechanism: the higher the molecular weight of the polymer, the 
slower the in vitro release of the drug (Kumari, 2010; Zambaux, 1999). The 
loading of the drug into the core of particles can be achieved by 
incorporation of the molecule during the nanoparticle production 
(Danhier, 2012). This approach prevents agglutination of the drug with 
plasmatic proteins or its retention in the liver, spleen, or other organs such 
as the lungs. Hydrophobic NPs are rapidly opsonized and cleared by the 
macrophages of the mononuclear phagocytic system. Thus the surface of 
this type of NPs must be modified with specific molecules to increase their 
  
 
Chapter 2 23 
 
circulation time in the blood (Brigger, 2002; Kumari, 2010). The 
nanoparticle surface needs also to be altered for the system to be able to 
cross the BBB and normally the modifications are based on: a) covalent 
attachment of PEG, b) coating with certain surfactants that should have 
PEG fragments in their structure and c) covalent attachment or adsorption 
of targeting molecules (Wohlfart, 2012).  
Liposomes are one of the more studied vehicles to transport drugs 
to the site of action and several improvements were achieved during the 
last decades (Lai, 2013). The addition of PEG molecules is the more 
relevant progress since it allowed the increase of the stability and 
bioavailability of the systems (Torchilin, 1994). PEG protects the 
liposomes from clearance by cells of the reticulo-endothelial system. The 
increase of the half life time up to 90 hours in humans, due to a reduced 
uptake by the liver and spleen, was an important feature for the use of 
these systems in drug delivery (Gabizon, 2003; Papahadjopoulos, 1991; 
Torchilin, 1996). PEG also rendered the dose independent from the blood 
clearance kinetics for a wide range of drug dosages (Papahadjopoulos, 
1991). Several experiments confirmed the benefits of PEG as a steric 
stabilizer (Blume, 1990; Klibanov, 1990; Papahadjopoulos, 1991). These 
carriers can be prepared synthetically at high purity and in large 
quantities, which has led to its acceptance for clinical applications 
(Schnyder, 2005). Liposomes are considered non-toxic, biocompatible and 
fully biodegradable carriers (Salvati, 2013; Torchilin, 2005). There are 
already some formulations based on liposomes that are used in clinics: 
Ambisome® (Gilead Sciences, Foster City, CA, USA) in which the 
encapsulated drug is the antifungal amphotericin B (Veerareddy and 
Vobalaboina 2004), Myocet® (Elan Pharmaceuticals Inc., Princeton, NJ, 
USA) has the anticancer agent doxorubicin (Alberts et al 2004), and 
Daunoxome® (Gilead Sciences), in which the incorporated drug is 
daunorubicin (Allen and Martin 2004).  In vivo studies have shown that 
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liposomes can decrease the toxicity of several drugs leading to recent 
clinical trials of other formulations, which have shown promising results 
(Immordino, 2006).  
Normally, the lipids used in liposomes are phospholipids that form 
a cell membrane-like phospholipid-bilayer structure. Liposomes contain a 
hydrophilic phase inside the core and a lipophilic phase between the 
bilayers and thus they can carry either hydrophilic or lipophilic molecules 
(Huang, 2013; Torchilin, 2005). The phospholipids can originate 
liposomes of various sizes like small unilamellar vesicles (SUVs) with 
diameters inferior of 100 nm and multilamellar vesicles (MLVs) with 
diameters between 100 and 1000 nm (Samad, 2007; Vyas, 2001). SUVs are 
preferred for an efficient and constant drug release. Besides 
phospholipids, cholesterol is also added to the formulations to increase 
the circulation time of the liposomes in the blood through the increase of 
their stability (Papahadjopoulos, 1991). PEGylation of liposomes enhances 
their hydrophilicity making these carriers non ideal brain delivery 
systems for crossing the BBB (Huang, 2013). However after surface 
modification with antibodies, they have shown promising results for the 
transport of drugs through the BBB. 
 
2.7. Monoclonal antibodies 
Monoclonal antibodies are being used for targeting drugs, proteins 
and peptides to the brain (Alam, 2010). Köhler and Milstein developed a 
hybridoma technique that allows to obtain large quantities of mAbs with a 
unique specificity, which accelerates the use of antibodies and immuno-
conjugates in therapy (Kohler, 1975). Antibodies have long serum half-
lives and are both hydrophilic and large molecules (approximately 150 
kDa), which hinder them from entering the BBB through simple diffusion. 
Empirical evidence shows that intravenously injected antibodies have a 
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low efficiency in reaching the brain. Such antibodies do not reach high 
enough therapeutic concentrations in the CNS because their accumulation 
in the brain is shortened by an apparent efflux system (Banks, 2008; 
Frank, 2011). However antibodies can be used as active targeting 
molecules to BBB receptors, allowing the passage of drugs through this 
barrier by RMT (Calvo, 2001; Huang, 2013). This transport mechanism 
seems to be one of the more promising strategies in drug delivery to the 
brain due to the high incorporation capacity, reduction of side effects and 
circumvention of the multidrug efflux system (Bao, 2012; Calvo, 2001). 
Some high molecular weight molecules including insulin, insulin-like 
growth factor, melanotransferrin, transferrin and vasopressin have 
receptors at the luminal side of the endothelial cells of the BBB and are 
transported via RMT (Table 2.2) (Demeule, 2002; Frank, 2011). These 
transportation systems are saturable, which means that they have a finite 
capacity to bind and transport their ligands. The rate of transmembrane 
diffusion of molecules across the BBB is generally lower than it would be 
expected for a transport mediated by receptors (Banks, 2009; Frank, 
2011). The transferrin receptor (TfR) is very concentrated in brain 
capillary endothelium, comparatively to other organs, making it a 
desirable target for enhanced drug delivery to the brain (Carroll, 2010). 
Despite the increased use of transferrin as ligand for brain targeting, its 
application in vivo is very limited (Chang, 2009; Visser, 2005). Endogenous 
levels of transferrin are very high, which results in a saturation of the TfR 
(de Boer, 2007; van Rooy, 2011).  
The antibodies against the TfR are thus preferable than the P-gp. 
The mAb for TfR does not compete with the natural transferrin present in 
the blood circulation (Lee, 2000). Antibodies against the TfR (for example, 
OX-26 mAb) have been investigated in a number of studies (Huwyler, 
1996; Kuo, 2011; Zhang, 2003). Radiolabeling and immuno-histochemical 
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approaches were used to study the brain penetration of OX-26 mAb (Gosk, 
2004; Moos, 2001; Paris-Robidas, 2011). 
 
Table 2.2 - Receptors at the brain endothelial cells that could be used as  
targets for brain drug delivery (Alam, 2010; Dehouck, 1997; Fillebeen, 
1999; Wu, 1999). 
Receptors Molecules 
Insulin Receptor Insulin 
Transferrin Receptor Transferrin 
Insulin-like growth factor receptors 
Insulin-like growth factor 1 and 2, mannose-6-
phosphate 
Leptin receptor Leptin 
Fc like growth factor receptor Immunoglobulin G 
Scavenger receptor type B1 
Modified lipoproteins, like acetylated low density 
lipoprotein (LDL) 
LDL receptor LDL  
Lactoferrin receptor Lactoferrin  
Interleukin 1 receptor Interleukin 1  
Folic acid receptor Folic acid 
 
The studies showed that OX-26 is transported into brain capillary 
endothelial cells but does not penetrate into the CNS at appreciable 
concentrations (Couch, 2013). As OX-26 is directed against the rat TfR, 
other mAbs were used to target the mouse TfR, including the 8D3 (Kissel, 
1998) and the RI7217 mAbs (Lesley, 1984), and are reported to associate 
to human TfR in vitro, probably due to the 86% homology between mouse 
and human receptors (Table 2.3) (Salvati, 2013; Wang, 2008). In vitro 
experiments performed by van Rooy et. al. showed that RI7217 binds 
significantly to human endothelial cells (hCMEC/D3) (van Rooy, 2011). 
A receptor frequently found in the human brain endothelial cells is 
the insulin receptor (IR) and its antibody is the most potent mAb 
discovered until today (Alam, 2010). Kuo et al. used the 83-14 human mAb 
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to target the IR and proved that it is 10 times more efficient than the anti-
transferrin mAb to target TfR (Kuo, 2013; Walus, 1996). The 83-14 mAb 
has a strong affinity to brain capillary and can bind with a subunit of the 
human IR (Prigent, 1990). As the size of the 83-14 mAb is similar to the 
neuroactive molecule, its transport is effective (Boado, 2007; Kuo, 2013) 
(Table 2.3).  
 
Table 2.3 - mAbs specific for brain receptors and their reactivity (Alam, 
2010; Boado, 2011; Boado, 2007; Boado, 2009; Chekhonin, 2005; Lee, 2000; 
Ng, 2000; Pardridge, 1991; Pardridge, 1995; Salvati, 2013) 
Targeting mAb Target receptor Reactivity 
Murine OX26 TfR Rat, Human 
Rat 8D3 TfR Mouse 
Murine 8314 IR Human 
Chimeric anti-TfR TfR Mouse 
Humanized anti-IR IR Human 
RI7217 TfR Mouse, Human 
Chimeric anti-IR IR Human 
HYB-241 P-gp Human 
D4 
gliofibrillary acidic 
protein 
Human, Rat 
Anti-E-selectin E-selectin Human 
 
2.7.1. Immuno-nanocarriers  
Nanosystems coupled to mAbs that can be recognized by the BBB 
receptors are being studied for the development of nano-drug delivery 
systems to treat CNS disorders (Alam, 2010). The principal reason to the 
worldwide acceptance of these carriers is their controlled properties and 
the ability of releasing the drug at the selected target site. Immuno-
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targeted drug delivery systems have several advantages that include a 
high capacity of drug loading, the relatively few mAbs necessary to achieve 
high levels of drug targeting, a protection of the encapsulated drug from 
degradation in the biological environment and the ability to provide 
stimulus-sensitive compositions for controlled and enhanced release of 
the drug in the targeting areas (Koshkaryev, 2013). In order to meet the 
requirements of a “Directed Trojan horse”, the antibody must bind to the 
brain microvascular endothelial cells, specifically to a transcytosis 
receptor, with sufficient affinity. After binding, the transcytosis pathway 
needs to be activated (Frank, 2011; Kuo, 2013; Pardridge, 1999). 
Therapies with the use of these immuno-targeting systems may be more 
efficient by directing the drug to diseased cells and reducing unnecessary 
delivery of excessive amounts of drugs into the bloodstream (Pedro 
Ramos-Cabrer, 2013).  
The BBB TfR is a bidirectional transcytosis system (Zhang, 2001), 
and mediates the transport of the system through the endothelial barrier 
into the brain interstitial space. In the case of the liposomes, they fuse with 
the intracellular endosomal membrane subsequent to endocytosis and 
release the drug into the cytosol of the target cell (Figure 2.4) (Mok, 1999; 
Shi, 2001).  
Chekhonin et al. tested the D4 mAb against human gliofibrillary 
acidic protein as a potential vector to direct immunoliposomes against 
embryonic rat brain astrocytes. These immunoliposomes (palmitoyl-oleyl-
phosphatidylcholine, cholesterol, maleimido-4-(p-phenylbutyryl)-
phosphatidylethanolamine and distearoylphosphatidylethanolamine-
PEG2000) may be useful to deliver drugs to the glial brain cells or to loci in 
the brain with a partially disintegrated BBB. The referred system cannot 
be applied to the treatment of neurodegenerative diseases such as 
Alzheimer or Parkinson, but could be used for the treatment of other brain 
pathologies in which the BBB integrity is altered (Chekhonin, 2005). 
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Figure 2.4 - Schematic representation of the interaction between 
immunoliposomes and cells. Adapted from (Acharya, 2011). 
 
HYB-241 is a mouse antihuman P-gp mAb and was used by             
Ng et al. to target liposomes (dioleoylphosphatidylethanolamine, 
dioleoylphosphatidylethanolamine-PEG2000, dioleoylphosphatidic acid and 
N-glutarylphosphatidylethanolamine) to the brain. This nanocarrier 
induces a bilayer destabilization of the BBB that results in a site-specific 
release of the liposome contents (Ng, 2000). 
 
References 
Acharya, S.; Sahoo, S. K. 2011. PLGA nanoparticles containing various 
anticancer agents and tumour delivery by EPR effect. Adv Drug 
Deliv Rev. Vol. 63. n.º 3. p. 170-83. 
  
 
30 Chapter 2 
 
Alam, M. I.; Beg, S.; Samad, A.; Baboota, S.; Kohli, K.; Ali, J.; Ahuja, A.; Akbar, 
M. 2010. Strategy for effective brain drug delivery. Eur J Pharm 
Sci. Vol. 40. n.º 5. p. 385-403. 
Andreasen, N.; Blennow, K. 2002. beta-amyloid (A beta) protein in 
cerebrospinal fluid as a biomarker for Alzheimer's disease. 
Peptides. Vol. 23. n.º 7. p. 1205-1214. 
Andrieux, K.; Couvreur, P. 2009. Polyalkylcyanoacrylate nanoparticles for 
delivery of drugs across the blood-brain barrier. Wiley Interdiscip 
Rev Nanomed Nanobiotechnol. Vol. 1. n.º 5. p. 463-74. 
Austen, B. M.; Paleologou, K. E.; Ali, S. A.; Qureshi, M. M.; Allsop, D.; El-
Agnaf, O. M. 2008. Designing peptide inhibitors for 
oligomerization and toxicity of Alzheimer's beta-amyloid peptide. 
Biochemistry. Vol. 47. n.º 7. p. 1984-92. 
Banks, R. E.; Smart, B. E.; Tatlow, J. C. - Organofluorine chemistry : 
principles and commercial applications. New York: Plenum, 1994.  
Banks, W. A. 2008. Developing drugs that can cross the blood-brain 
barrier: applications to Alzheimer's disease. BMC Neurosci. Vol. 9 
Suppl 3. p. S2. 
Banks, W. A. 2009. Characteristics of compounds that cross the blood-
brain barrier. Bmc Neurology. Vol. 9.  
Bao, H.; Jin, X.; Li, L.; Lv, F.; Liu, T. 2012. OX26 modified hyperbranched 
polyglycerol-conjugated poly(lactic-co-glycolic acid) 
nanoparticles: synthesis, characterization and evaluation of its 
brain delivery ability. J Mater Sci Mater Med. Vol. 23. n.º 8. p. 1891-
901. 
Begley, D. J. 1996. The blood-brain barrier: principles for targeting 
peptides and drugs to the central nervous system. J Pharm 
Pharmacol. Vol. 48. n.º 2. p. 136-46. 
  
 
Chapter 2 31 
 
Berg, T. 2003. Modulation of protein-protein interactions with small 
organic molecules. Angew Chem Int Ed Engl. Vol. 42. n.º 22. p. 
2462-81. 
Bernacki, J.; Dobrowolska, A.; Nierwinska, K.; Malecki, A. 2008. Physiology 
and pharmacological role of the blood-brain barrier. Pharmacol 
Rep. Vol. 60. n.º 5. p. 600-22. 
Blume, G.; Cevc, G. 1990. Liposomes for the sustained drug release in vivo. 
Biochim Biophys Acta. Vol. 1029. n.º 1. p. 91-7. 
Boado, R. J.; Pardridge, W. M. 2011. The Trojan Horse Liposome 
Technology for Nonviral Gene Transfer across the Blood-Brain 
Barrier. J Drug Deliv. Vol. 2011. p. 296151. 
Boado, R. J.; Zhang, Y.; Pardridge, W. M. 2007. Humanization of anti-human 
insulin receptor antibody for drug targeting across the human 
blood-brain barrier. Biotechnol Bioeng. Vol. 96. n.º 2. p. 381-91. 
Boado, R. J.; Zhang, Y.; Wang, Y.; Pardridge, W. M. 2009. Engineering and 
expression of a chimeric transferrin receptor monoclonal 
antibody for blood-brain barrier delivery in the mouse. Biotechnol 
Bioeng. Vol. 102. n.º 4. p. 1251-8. 
Brambilla, D.; Le Droumaguet, B.; Nicolas, J.; Hashemi, S. H.; Wu, L. P.; 
Moghimi, S. M.; Couvreur, P.; Andrieux, K. 2011. Nanotechnologies 
for Alzheimer's disease: diagnosis, therapy, and safety issues. 
Nanomedicine. Vol. 7. n.º 5. p. 521-40. 
Brigger, I.; Dubernet, C.; Couvreur, P. 2002. Nanoparticles in cancer 
therapy and diagnosis. Adv Drug Deliv Rev. Vol. 54. n.º 5. p. 631-51. 
Brookmeyer, R.; Johnson, E.; Ziegler-Graham, K.; Arrighi, H. M. 2007. 
Forecasting the global burden of Alzheimer's disease. Alzheimers 
Dement. Vol. 3. n.º 3. p. 186-91. 
  
 
32 Chapter 2 
 
Calhoun, M. E.; Burgermeister, P.; Phinney, A. L.; Stalder, M.; Tolnay, M.; 
Wiederhold, K. H.; Abramowski, D.; Sturchler-Pierrat, C.; Sommer, 
B.; Staufenbiel, M.; Jucker, M. 1999. Neuronal overexpression of 
mutant amyloid precursor protein results in prominent 
deposition of cerebrovascular amyloid. Proc Natl Acad Sci U S A. 
Vol. 96. n.º 24. p. 14088-93. 
Calvo, P.; Gouritin, B.; Chacun, H.; Desmaele, D.; D'Angelo, J.; Noel, J. P.; 
Georgin, D.; Fattal, E.; Andreux, J. P.; Couvreur, P. 2001. Long-
circulating PEGylated polycyanoacrylate nanoparticles as new 
drug carrier for brain delivery. Pharm Res. Vol. 18. n.º 8. p. 1157-
66. 
Carroll, R. T.; Bhatia, D.; Geldenhuys, W.; Bhatia, R.; Miladore, N.; Bishayee, 
A.; Sutariya, V. 2010. Brain-targeted delivery of Tempol-loaded 
nanoparticles for neurological disorders. J Drug Target. Vol. 18. n.º 
9. p. 665-74. 
Chacon, M. A.; Barria, M. I.; Soto, C.; Inestrosa, N. C. 2004. Beta-sheet 
breaker peptide prevents Abeta-induced spatial memory 
impairments with partial reduction of amyloid deposits. Mol 
Psychiatry. Vol. 9. n.º 10. p. 953-61. 
Chang, J.; Jallouli, Y.; Kroubi, M.; Yuan, X. B.; Feng, W.; Kang, C. S.; Pu, P. Y.; 
Betbeder, D. 2009. Characterization of endocytosis of transferrin-
coated PLGA nanoparticles by the blood-brain barrier. Int J Pharm. 
Vol. 379. n.º 2. p. 285-92. 
Chekhonin, V. P.; Zhirkov, Y. A.; Gurina, O. I.; Ryabukhin, I. A.; Lebedev, S. 
V.; Kashparov, I. A.; Dmitriyeva, T. B. 2005. PEGylated 
immunoliposomes directed against brain astrocytes. Drug Deliv. 
Vol. 12. n.º 1. p. 1-6. 
Chou, P. Y.; Fasman, G. D. 1978. Empirical predictions of protein 
conformation. Annu Rev Biochem. Vol. 47. p. 251-76. 
  
 
Chapter 2 33 
 
Clippingdale, A. B.; Wade, J. D.; Barrow, C. J. 2001. The amyloid-beta 
peptide and its role in Alzheimer's disease. J Pept Sci. Vol. 7. n.º 5. 
p. 227-49. 
Couch, J. A.; Yu, Y. J.; Zhang, Y.; Tarrant, J. M.; Fuji, R. N.; Meilandt, W. J.; 
Solanoy, H.; Tong, R. K.; Hoyte, K.; Luk, W.; Lu, Y.; Gadkar, K.; 
Prabhu, S.; Ordonia, B. A.; Nguyen, Q.; Lin, Y.; Lin, Z.; Balazs, M.; 
Scearce-Levie, K.; Ernst, J. A.; Dennis, M. S.; Watts, R. J. 2013. 
Addressing safety liabilities of TfR bispecific antibodies that cross 
the blood-brain barrier. Sci Transl Med. Vol. 5. n.º 183. p. 183ra57, 
1-12. 
Crone, C.; Christensen, O. 1981. Electrical resistance of a capillary 
endothelium. J Gen Physiol. Vol. 77. n.º 4. p. 349-71. 
Crone, C.; Olesen, S. P. 1982. Electrical resistance of brain microvascular 
endothelium. Brain Res. Vol. 241. n.º 1. p. 49-55. 
Csuk, R.; Albert, S.; Kluge, R.; Strohl, D. 2013. Resveratrol derived 
butyrylcholinesterase inhibitors. Arch Pharm (Weinheim). Vol. 
346. n.º 7. p. 499-503. 
Danhier, F.; Ansorena, E.; Silva, J. M.; Coco, R.; Le Breton, A.; Preat, V. 2012. 
PLGA-based nanoparticles: an overview of biomedical 
applications. J Control Release. Vol. 161. n.º 2. p. 505-22. 
Datki, Z.; Papp, R.; Zadori, D.; Soos, K.; Fulop, L.; Juhasz, A.; Laskay, G.; 
Hetenyi, C.; Mihalik, E.; Zarandi, M.; Penke, B. 2004. In vitro model 
of neurotoxicity of Abeta 1-42 and neuroprotection by a 
pentapeptide: irreversible events during the first hour. Neurobiol 
Dis. Vol. 17. n.º 3. p. 507-15. 
de Boer, A. G.; Gaillard, P. J. 2007. Drug targeting to the brain. Annu Rev 
Pharmacol Toxicol. Vol. 47. p. 323-55. 
  
 
34 Chapter 2 
 
Dehouck, B.; Fenart, L.; Dehouck, M. P.; Pierce, A.; Torpier, G.; Cecchelli, R. 
1997. A new function for the LDL receptor: transcytosis of LDL 
across the blood-brain barrier. J Cell Biol. Vol. 138. n.º 4. p. 877-89. 
Demeule, M.; Poirier, J.; Jodoin, J.; Bertrand, Y.; Desrosiers, R. R.; Dagenais, 
C.; Nguyen, T.; Lanthier, J.; Gabathuler, R.; Kennard, M.; Jefferies, 
W. A.; Karkan, D.; Tsai, S.; Fenart, L.; Cecchelli, R.; Beliveau, R. 
2002. High transcytosis of melanotransferrin (P97) across the 
blood-brain barrier. J Neurochem. Vol. 83. n.º 4. p. 924-33. 
Egleton, R. D.; Davis, T. P. 1997. Bioavailability and transport of peptides 
and peptide drugs into the brain. Peptides. Vol. 18. n.º 9. p. 1431-9. 
Esler, W. P.; Stimson, E. R.; Ghilardi, J. R.; Felix, A. M.; Lu, Y. A.; Vinters, H. 
V.; Mantyh, P. W.; Maggio, J. E. 1997. A beta deposition inhibitor 
screen using synthetic amyloid. Nat Biotechnol. Vol. 15. n.º 3. p. 
258-63. 
Fillebeen, C.; Descamps, L.; Dehouck, M. P.; Fenart, L.; Benaissa, M.; Spik, G.; 
Cecchelli, R.; Pierce, A. 1999. Receptor-mediated transcytosis of 
lactoferrin through the blood-brain barrier. J Biol Chem. Vol. 274. 
n.º 11. p. 7011-7. 
Filler, Robert; Kobayashi, Yoshir o; American Chemical Society.; Nihon 
Kagakkai. - Biomedicinal aspects of fluorine chemistry. 
Amsterdam ; New York, U.S.A.: Elsevier Biomedical Press ; 
Findeis, M. A. 2000. Approaches to discovery and characterization of 
inhibitors of amyloid beta-peptide polymerization. Biochim 
Biophys Acta. Vol. 1502. n.º 1. p. 76-84. 
Findeis, M. A. 2002. Peptide inhibitors of beta amyloid aggregation. Curr 
Top Med Chem. Vol. 2. n.º 4. p. 417-23. 
 
  
 
Chapter 2 35 
 
Findeis, M. A.; Musso, G. M.; Arico-Muendel, C. C.; Benjamin, H. W.; Hundal, 
A. M.; Lee, J. J.; Chin, J.; Kelley, M.; Wakefield, J.; Hayward, N. J.; 
Molineaux, S. M. 1999. Modified-peptide inhibitors of amyloid 
beta-peptide polymerization. Biochemistry. Vol. 38. n.º 21. p. 6791-
800. 
Forstl, H.; Kurz, A. 1999. Clinical features of Alzheimer's disease. Eur Arch 
Psychiatry Clin Neurosci. Vol. 249. n.º 6. p. 288-90. 
Frank, R. T.; Aboody, K. S.; Najbauer, J. 2011. Strategies for enhancing 
antibody delivery to the brain. Biochim Biophys Acta. Vol. 1816. n.º 
2. p. 191-8. 
Fricker, G.; Miller, D. S. 2004. Modulation of drug transporters at the 
blood-brain barrier. Pharmacology. Vol. 70. n.º 4. p. 169-76. 
Frydman-Marom, A.; Rechter, M.; Shefler, I.; Bram, Y.; Shalev, D. E.; Gazit, E. 
2009. Cognitive-performance recovery of Alzheimer's disease 
model mice by modulation of early soluble amyloidal assemblies. 
Angew Chem Int Ed Engl. Vol. 48. n.º 11. p. 1981-6. 
Funke, S. A.; Willbold, D. 2012. Peptides for therapy and diagnosis of 
Alzheimer's disease. Curr Pharm Des. Vol. 18. n.º 6. p. 755-67. 
Gabizon, A.; Shmeeda, H.; Barenholz, Y. 2003. Pharmacokinetics of 
pegylated liposomal Doxorubicin: review of animal and human 
studies. Clin Pharmacokinet. Vol. 42. n.º 5. p. 419-36. 
Giacomelli, C. E.; Norde, W. 2003. Influence of hydrophobic Teflon 
particles on the structure of amyloid beta-peptide. 
Biomacromolecules. Vol. 4. n.º 6. p. 1719-26. 
 
 
  
 
36 Chapter 2 
 
Gordon, D. J.; Sciarretta, K. L.; Meredith, S. C. 2001. Inhibition of beta-
amyloid(40) fibrillogenesis and disassembly of beta-amyloid(40) 
fibrils by short beta-amyloid congeners containing N-methyl 
amino acids at alternate residues. Biochemistry. Vol. 40. n.º 28. p. 
8237-45. 
Granger, B.; Albu, S. 2005. The haloperidol story. Ann Clin Psychiatry. Vol. 
17. n.º 3. p. 137-40. 
Haass, C.; Schlossmacher, M. G.; Hung, A. Y.; Vigopelfrey, C.; Mellon, A.; 
Ostaszewski, B. L.; Lieberburg, I.; Koo, E. H.; Schenk, D.; Teplow, D. 
B.; Selkoe, D. J. 1992. Amyloid Beta-Peptide Is Produced by 
Cultured-Cells during Normal Metabolism. Nature. Vol. 359. n.º 
6393. p. 322-325. 
Haass, C.; Selkoe, D. J. 1993. Cellular processing of beta-amyloid precursor 
protein and the genesis of amyloid beta-peptide. Cell. Vol. 75. n.º 6. 
p. 1039-42. 
Haass, C.; Selkoe, D. J. 2007. Soluble protein oligomers in 
neurodegeneration: lessons from the Alzheimer's amyloid beta-
peptide. Nat Rev Mol Cell Biol. Vol. 8. n.º 2. p. 101-12. 
Hardy, J. A.; Higgins, G. A. 1992. Alzheimer's disease: the amyloid cascade 
hypothesis. Science. Vol. 256. n.º 5054. p. 184-5. 
Hardy, J.; Selkoe, D. J. 2002a. The amyloid hypothesis of Alzheimer's 
disease: progress and problems on the road to therapeutics. 
Science. Vol. 297. n.º 5580. p. 353-6. 
Hardy, J.; Selkoe, D. J. 2002b. Medicine - The amyloid hypothesis of 
Alzheimer's disease: Progress and problems on the road to 
therapeutics. Science. Vol. 297. n.º 5580. p. 353-356. 
 
  
 
Chapter 2 37 
 
Hartmann, T.; Bieger, S. C.; Bruhl, B.; Tienari, P. J.; Ida, N.; Allsop, D.; 
Roberts, G. W.; Masters, C. L.; Dotti, C. G.; Unsicker, K.; Beyreuther, 
K. 1997. Distinct sites of intracellular production for Alzheimer's 
disease A beta40/42 amyloid peptides. Nat Med. Vol. 3. n.º 9. p. 
1016-20. 
Hilbich, C.; Kisters-Woike, B.; Reed, J.; Masters, C. L.; Beyreuther, K. 1992. 
Substitutions of hydrophobic amino acids reduce the 
amyloidogenicity of Alzheimer's disease beta A4 peptides. J Mol 
Biol. Vol. 228. n.º 2. p. 460-73. 
Huang, F. Y.; Chen, W. J.; Lee, W. Y.; Lo, S. T.; Lee, T. W.; Lo, J. M. 2013. In 
vitro and in vivo evaluation of lactoferrin-conjugated liposomes as 
a novel carrier to improve the brain delivery. Int J Mol Sci. Vol. 14. 
n.º 2. p. 2862-74. 
Hughes, S. R.; Goyal, S.; Sun, J. E.; Gonzalez-DeWhitt, P.; Fortes, M. A.; 
Riedel, N. G.; Sahasrabudhe, S. R. 1996. Two-hybrid system as a 
model to study the interaction of beta-amyloid peptide monomers. 
Proc Natl Acad Sci U S A. Vol. 93. n.º 5. p. 2065-70. 
Immordino, M. L.; Dosio, F.; Cattel, L. 2006. Stealth liposomes: review of 
the basic science, rationale, and clinical applications, existing and 
potential. Int J Nanomedicine. Vol. 1. n.º 3. p. 297-315. 
Iversen, L. 2002. Amyloid diseases: small drugs lead the attack. Nature. 
Vol. 417. n.º 6886. p. 231-3. 
J.L. Fauchere, C. Thurieau. 1992. Evaluation of the Stability of Peptides and 
Pseudopeptides as a Tool in Peptide Drug Design. Advances in 
Drug Research. Vol. 23. p. 127-159. 
Jahn, T. R.; Radford, S. E. 2005. The Yin and Yang of protein folding. FEBS J. 
Vol. 272. n.º 23. p. 5962-70. 
  
 
38 Chapter 2 
 
Jan, A.; Gokce, O.; Luthi-Carter, R.; Lashuel, H. A. 2008. The ratio of 
monomeric to aggregated forms of Abeta40 and Abeta42 is an 
important determinant of amyloid-beta aggregation, 
fibrillogenesis, and toxicity. J Biol Chem. Vol. 283. n.º 42. p. 28176-
89. 
Jarrett, J. T.; Berger, E. P.; Lansbury, P. T. 1993a. The Carboxy Terminus of 
the Beta-Amyloid Protein Is Critical for the Seeding of Amyloid 
Formation - Implications for the Pathogenesis of Alzheimers-
Disease. Biochemistry. Vol. 32. n.º 18. p. 4693-4697. 
Jarrett, J. T.; Berger, E. P.; Lansbury, P. T., Jr. 1993b. The carboxy terminus 
of the beta amyloid protein is critical for the seeding of amyloid 
formation: implications for the pathogenesis of Alzheimer's 
disease. Biochemistry. Vol. 32. n.º 18. p. 4693-7. 
Jefferies, W. A.; Brandon, M. R.; Hunt, S. V.; Williams, A. F.; Gatter, K. C.; 
Mason, D. Y. 1984. Transferrin receptor on endothelium of brain 
capillaries. Nature. Vol. 312. n.º 5990. p. 162-3. 
Juhasz, G.; Marki, A.; Vass, G.; Fulop, L.; Budai, D.; Penke, B.; Falkay, G.; 
Szegedi, V. 2009. An intraperitoneally administered pentapeptide 
protects against Abeta (1-42) induced neuronal excitation in vivo. 
J Alzheimers Dis. Vol. 16. n.º 1. p. 189-96. 
Kang, J.; Lemaire, H. G.; Unterbeck, A.; Salbaum, J. M.; Masters, C. L.; 
Grzeschik, K. H.; Multhaup, G.; Beyreuther, K.; Mullerhill, B. 1987. 
The Precursor of Alzheimers-Disease Amyloid-A4 Protein 
Resembles a Cell-Surface Receptor. Nature. Vol. 325. n.º 6106. p. 
733-736. 
Kayed, R.; Head, E.; Thompson, J. L.; McIntire, T. M.; Milton, S. C.; Cotman, C. 
W.; Glabe, C. G. 2003. Common structure of soluble amyloid 
oligomers implies common mechanism of pathogenesis. Science. 
Vol. 300. n.º 5618. p. 486-9. 
  
 
Chapter 2 39 
 
Kirk, K. L. 2006. Fluorine in medicinal chemistry: Recent therapeutic 
applications of fluorinated small molecules. Journal of Fluorine 
Chemistry. Vol. 127. n.º 8. p. 1013-1029. 
Kirsch, Peer - Modern fluoroorganic chemistry : synthesis, reactivity, 
applications. Weinheim: Wiley-VCH, 2004. 
Kirschner, D. A.; Abraham, C.; Selkoe, D. J. 1986. X-Ray-Diffraction from 
Intraneuronal Paired Helical Filaments and Extraneuronal 
Amyloid Fibers in Alzheimer-Disease Indicates Cross-Beta 
Conformation. Proceedings of the National Academy of Sciences of 
the United States of America. Vol. 83. n.º 2. p. 503-507. 
Kisilevsky, R.; Lemieux, L. J.; Fraser, P. E.; Kong, X.; Hultin, P. G.; Szarek, W. 
A. 1995. Arresting amyloidosis in vivo using small-molecule 
anionic sulphonates or sulphates: implications for Alzheimer's 
disease. Nat Med. Vol. 1. n.º 2. p. 143-8. 
Kissel, K.; Hamm, S.; Schulz, M.; Vecchi, A.; Garlanda, C.; Engelhardt, B. 
1998. Immunohistochemical localization of the murine 
transferrin receptor (TfR) on blood-tissue barriers using a novel 
anti-TfR monoclonal antibody. Histochem Cell Biol. Vol. 110. n.º 1. 
p. 63-72. 
Klibanov, A. L.; Maruyama, K.; Torchilin, V. P.; Huang, L. 1990. 
Amphipathic polyethyleneglycols effectively prolong the 
circulation time of liposomes. FEBS Lett. Vol. 268. n.º 1. p. 235-7. 
Kohler, G.; Milstein, C. 1975. Continuous cultures of fused cells secreting 
antibody of predefined specificity. Nature. Vol. 256. n.º 5517. p. 
495-7. 
 
 
  
 
40 Chapter 2 
 
Kokkoni, N.; Stott, K.; Amijee, H.; Mason, J. M.; Doig, A. J. 2006. N-
Methylated peptide inhibitors of beta-amyloid aggregation and 
toxicity. Optimization of the inhibitor structure. Biochemistry. Vol. 
45. n.º 32. p. 9906-18. 
Koshkaryev, A.; Sawant, R.; Deshpande, M.; Torchilin, V. 2013. 
Immunoconjugates and long circulating systems: origins, current 
state of the art and future directions. Adv Drug Deliv Rev. Vol. 65. 
n.º 1. p. 24-35. 
Kumari, A.; Yadav, S. K.; Yadav, S. C. 2010. Biodegradable polymeric 
nanoparticles based drug delivery systems. Colloids Surf B 
Biointerfaces. Vol. 75. n.º 1. p. 1-18. 
Kuo, Y. C.; Ko, H. F. 2013. Targeting delivery of saquinavir to the brain 
using 83-14 monoclonal antibody-grafted solid lipid 
nanoparticles. Biomaterials. Vol. 34. n.º 20. p. 4818-30. 
Kuperstein, I.; Broersen, K.; Benilova, I.; Rozenski, J.; Jonckheere, W.; 
Debulpaep, M.; Vandersteen, A.; Segers-Nolten, I.; Van Der Werf, 
K.; Subramaniam, V.; Braeken, D.; Callewaert, G.; Bartic, C.; 
D'Hooge, R.; Martins, I. C.; Rousseau, F.; Schymkowitz, J.; De 
Strooper, B. 2010. Neurotoxicity of Alzheimer's disease Abeta 
peptides is induced by small changes in the Abeta42 to Abeta40 
ratio. EMBO J. Vol. 29. n.º 19. p. 3408-20. 
Ladiwala, A. R.; Litt, J.; Kane, R. S.; Aucoin, D. S.; Smith, S. O.; Ranjan, S.; 
Davis, J.; Van Nostrand, W. E.; Tessier, P. M. 2012. Conformational 
differences between two amyloid beta oligomers of similar size 
and dissimilar toxicity. J Biol Chem. Vol. 287. n.º 29. p. 24765-73. 
 
 
  
 
Chapter 2 41 
 
Lai, F.; Fadda, A. M.; Sinico, C. 2013. Liposomes for brain delivery. Expert 
Opin Drug Deliv. Vol. 10. n.º 7. p. 1003-22. 
Larson, E. B.; Shadlen, M. F.; Wang, L.; McCormick, W. C.; Bowen, J. D.; Teri, 
L.; Kukull, W. A. 2004. Survival after initial diagnosis of Alzheimer 
disease. Annals of Internal Medicine. Vol. 140. n.º 7. p. 501-509. 
Lee, H. J.; Engelhardt, B.; Lesley, J.; Bickel, U.; Pardridge, W. M. 2000. 
Targeting rat anti-mouse transferrin receptor monoclonal 
antibodies through blood-brain barrier in mouse. J Pharmacol Exp 
Ther. Vol. 292. n.º 3. p. 1048-52. 
Lesley, J.; Hyman, R.; Schulte, R.; Trotter, J. 1984. Expression of transferrin 
receptor on murine hematopoietic progenitors. Cell Immunol. Vol. 
83. n.º 1. p. 14-25. 
Liu, H. F.; Ma, J.; Winter, C.; Bayer, R. 2010. Recovery and purification 
process development for monoclonal antibody production. MAbs. 
Vol. 2. n.º 5. p. 480-99. 
Makhaeva, G. F.; Aksinenko, A. Y.; Sokolov, V. B.; Serebryakova, O. G.; 
Richardson, R. J. 2009. Synthesis of organophosphates with 
fluorine-containing leaving groups as serine esterase inhibitors 
with potential for Alzheimer disease therapeutics. Bioorg Med 
Chem Lett. Vol. 19. n.º 19. p. 5528-30. 
Malamas, M. S.; Robichaud, A.; Erdei, J.; Quagliato, D.; Solvibile, W.; Zhou, 
P.; Morris, K.; Turner, J.; Wagner, E.; Fan, K.; Olland, A.; Jacobsen, 
S.; Reinhart, P.; Riddell, D.; Pangalos, M. 2010. Design and 
synthesis of aminohydantoins as potent and selective human beta-
secretase (BACE1) inhibitors with enhanced brain permeability. 
Bioorg Med Chem Lett. Vol. 20. n.º 22. p. 6597-605. 
  
 
42 Chapter 2 
 
Mason, J. M.; Kokkoni, N.; Stott, K.; Doig, A. J. 2003. Design strategies for 
anti-amyloid agents. Current Opinion in Structural Biology. Vol. 13. 
n.º 4. p. 526-532. 
Matharu, B.; El-Agnaf, O.; Razvi, A.; Austen, B. M. 2010. Development of 
retro-inverso peptides as anti-aggregation drugs for beta-amyloid 
in Alzheimer's disease. Peptides. Vol. 31. n.º 10. p. 1866-72. 
Mattson, M. P. 1997. Cellular actions of beta-amyloid precursor protein 
and its soluble and fibrillogenic derivatives. Physiol Rev. Vol. 77. 
n.º 4. p. 1081-132. 
McLaurin, J.; Golomb, R.; Jurewicz, A.; Antel, J. P.; Fraser, P. E. 2000. 
Inositol stereoisomers stabilize an oligomeric aggregate of 
Alzheimer amyloid beta peptide and inhibit abeta -induced 
toxicity. J Biol Chem. Vol. 275. n.º 24. p. 18495-502. 
Merlini, G.; Ascari, E.; Amboldi, N.; Bellotti, V.; Arbustini, E.; Perfetti, V.; 
Ferrari, M.; Zorzoli, I.; Marinone, M. G.; Garini, P.; et al. 1995. 
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with 
amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci U 
S A. Vol. 92. n.º 7. p. 2959-63. 
Merlini, G.; Bellotti, V. 2003. Molecular mechanisms of amyloidosis. N Engl 
J Med. Vol. 349. n.º 6. p. 583-96. 
Mok, K. W.; Lam, A. M.; Cullis, P. R. 1999. Stabilized plasmid-lipid particles: 
factors influencing plasmid entrapment and transfection 
properties. Biochim Biophys Acta. Vol. 1419. n.º 2. p. 137-50. 
Ng, K.; Zhao, L.; Liu, Y.; Mahapatro, M. 2000. The effects of 
polyethyleneglycol (PEG)-derived lipid on the activity of target-
sensitive immunoliposome. Int J Pharm. Vol. 193. n.º 2. p. 157-66. 
  
 
Chapter 2 43 
 
O'Hagan, D. 2008. Understanding organofluorine chemistry. An 
introduction to the C-F bond. Chem Soc Rev. Vol. 37. n.º 2. p. 308-
19. 
Ojima, Iwao; McCarthy, James R.; Welch, John T.; American Chemical 
Society. Division of Fluorine Chemistry.; American Chemical 
Society. Division of Medicinal Chemistry. - Biomedical frontiers of 
fluorine chemistry. Washington, DC: American Chemical Society, 
1996. 
Papahadjopoulos, D.; Allen, T. M.; Gabizon, A.; Mayhew, E.; Matthay, K.; 
Huang, S. K.; Lee, K. D.; Woodle, M. C.; Lasic, D. D.; Redemann, C.; et 
al. 1991. Sterically stabilized liposomes: improvements in 
pharmacokinetics and antitumor therapeutic efficacy. Proc Natl 
Acad Sci U S A. Vol. 88. n.º 24. p. 11460-4. 
Pappolla, M.; Bozner, P.; Soto, C.; Shao, H.; Robakis, N. K.; Zagorski, M.; 
Frangione, B.; Ghiso, J. 1998. Inhibition of Alzheimer beta-
fibrillogenesis by melatonin. J Biol Chem. Vol. 273. n.º 13. p. 7185-
8. 
Pardridge, W. M. 1999. Vector-mediated drug delivery to the brain. Adv 
Drug Deliv Rev. Vol. 36. n.º 2-3. p. 299-321. 
Pardridge, W. M. 2002. Drug and gene delivery to the brain: the vascular 
route. Neuron. Vol. 36. n.º 4. p. 555-8. 
Pardridge, W. M. 2007. Drug targeting to the brain. Pharm Res. Vol. 24. n.º 
9. p. 1733-44. 
Pardridge, W. M.; Buciak, J. L.; Friden, P. M. 1991. Selective transport of an 
anti-transferrin receptor antibody through the blood-brain 
barrier in vivo. J Pharmacol Exp Ther. Vol. 259. n.º 1. p. 66-70. 
 
  
 
44 Chapter 2 
 
Pardridge, W. M.; Kang, Y. S.; Buciak, J. L.; Yang, J. 1995. Human insulin 
receptor monoclonal antibody undergoes high affinity binding to 
human brain capillaries in vitro and rapid transcytosis through 
the blood-brain barrier in vivo in the primate. Pharm Res. Vol. 12. 
n.º 6. p. 807-16. 
Pedro Ramos-Cabrer, Francisco Campos. 2013. Liposomes and 
nanotechnology in drug development: focus on neurological 
targets. International Journal of Nanomedicine. Vol. 8. p. 951-960. 
Permanne, B.; Adessi, C.; Saborio, G. P.; Fraga, S.; Frossard, M. J.; Van Dorpe, 
J.; Dewachter, I.; Banks, W. A.; Van Leuven, F.; Soto, C. 2002. 
Reduction of amyloid load and cerebral damage in a transgenic 
mouse model of Alzheimer's disease by treatment with a beta-
sheet breaker peptide. FASEB J. Vol. 16. n.º 8. p. 860-2. 
Prigent, S. A.; Stanley, K. K.; Siddle, K. 1990. Identification of epitopes on 
the human insulin receptor reacting with rabbit polyclonal 
antisera and mouse monoclonal antibodies. J Biol Chem. Vol. 265. 
n.º 17. p. 9970-7. 
Risau, W. 1995. Differentiation of endothelium. FASEB J. Vol. 9. n.º 10. p. 
926-33. 
Rocha, S.; Cardoso, I.; Borner, H.; Pereira, M. C.; Saraiva, M. J.; Coelho, M. 
2009. Design and biological activity of beta-sheet breaker peptide 
conjugates. Biochem Biophys Res Commun. Vol. 380. n.º 2. p. 397-
401. 
Rowley, M.; Bristow, L. J.; Hutson, P. H. 2001. Current and novel 
approaches to the drug treatment of schizophrenia. J Med Chem. 
Vol. 44. n.º 4. p. 477-501. 
 
  
 
Chapter 2 45 
 
Salvati, E.; Re, F.; Sesana, S.; Cambianica, I.; Sancini, G.; Masserini, M.; 
Gregori, M. 2013. Liposomes functionalized to overcome the 
blood-brain barrier and to target amyloid-beta peptide: the 
chemical design affects the permeability across an in vitro model. 
Int J Nanomedicine. Vol. 8. p. 1749-58. 
Samad, A.; Sultana, Y.; Aqil, M. 2007. Liposomal drug delivery systems: an 
update review. Curr Drug Deliv. Vol. 4. n.º 4. p. 297-305. 
Schnyder, A.; Huwyler, J. 2005. Drug transport to brain with targeted 
liposomes. NeuroRx. Vol. 2. n.º 1. p. 99-107. 
Schwarzman, A. L.; Tsiper, M.; Gregori, L.; Goldgaber, D.; Frakowiak, J.; 
Mazur-Kolecka, B.; Taraskina, A.; Pchelina, S.; Vitek, M. P. 2005. 
Selection of peptides binding to the amyloid b-protein reveals 
potential inhibitors of amyloid formation. Amyloid. Vol. 12. n.º 4. p. 
199-209. 
Selkoe, D. J. 1991. The molecular pathology of Alzheimer's disease. 
Neuron. Vol. 6. n.º 4. p. 487-98. 
Selkoe, D. J. 2001. Presenilins, beta-amyloid precursor protein and the 
molecular basis of Alzheimer's disease. Clinical Neuroscience 
Research. Vol. 1. n.º 1-2. p. 91-103. 
Selkoe, D. J.; Wolfe, M. S. 2007. Presenilin: running with scissors in the 
membrane. Cell. Vol. 131. n.º 2. p. 215-21. 
Shankar, G. M.; Bloodgood, B. L.; Townsend, M.; Walsh, D. M.; Selkoe, D. J.; 
Sabatini, B. L. 2007. Natural oligomers of the Alzheimer amyloid-
beta protein induce reversible synapse loss by modulating an 
NMDA-type glutamate receptor-dependent signaling pathway. J 
Neurosci. Vol. 27. n.º 11. p. 2866-75. 
 
  
 
46 Chapter 2 
 
Shankar, G. M.; Li, S.; Mehta, T. H.; Garcia-Munoz, A.; Shepardson, N. E.; 
Smith, I.; Brett, F. M.; Farrell, M. A.; Rowan, M. J.; Lemere, C. A.; 
Regan, C. M.; Walsh, D. M.; Sabatini, B. L.; Selkoe, D. J. 2008. 
Amyloid-beta protein dimers isolated directly from Alzheimer's 
brains impair synaptic plasticity and memory. Nat Med. Vol. 14. n.º 
8. p. 837-42. 
Shi, N.; Boado, R. J.; Pardridge, W. M. 2001. Receptor-mediated gene 
targeting to tissues in vivo following intravenous administration 
of pegylated immunoliposomes. Pharm Res. Vol. 18. n.º 8. p. 1091-
5. 
Smart, B. E. 2001. Fluorine substituent effects (on bioactivity). Journal of 
Fluorine Chemistry. Vol. 109. n.º 1. p. 3-11. 
Soloshonok, V. A. - Enantiocontrolled synthesis of fluoro-organic 
compounds : stereochemical challenges and biomedical targets. 
Chichester ; New York: Wiley, 1999. 
Sood, A.; Abid, M.; Sauer, C.; Hailemichael, S.; Foster, M.; Torok, B.; Torok, 
M. 2011. Disassembly of preformed amyloid beta fibrils by small 
organofluorine molecules. Bioorg Med Chem Lett. Vol. 21. n.º 7. p. 
2044-7. 
Soto, C.; Kindy, M. S.; Baumann, M.; Frangione, B. 1996. Inhibition of 
Alzheimer's amyloidosis by peptides that prevent beta-sheet 
conformation. Biochem Biophys Res Commun. Vol. 226. n.º 3. p. 
672-80. 
Soto, C.; Sigurdsson, E. M.; Morelli, L.; Kumar, R. A.; Castano, E. M.; 
Frangione, B. 1998. Beta-sheet breaker peptides inhibit 
fibrillogenesis in a rat brain model of amyloidosis: implications for 
Alzheimer's therapy. Nat Med. Vol. 4. n.º 7. p. 822-6. 
  
 
Chapter 2 47 
 
Stine, W. B., Jr.; Dahlgren, K. N.; Krafft, G. A.; LaDu, M. J. 2003. In vitro 
characterization of conditions for amyloid-beta peptide 
oligomerization and fibrillogenesis. J Biol Chem. Vol. 278. n.º 13. p. 
11612-22. 
Strittmatter, W. J.; Saunders, A. M.; Schmechel, D.; Pericak-Vance, M.; 
Enghild, J.; Salvesen, G. S.; Roses, A. D. 1993. Apolipoprotein E: 
high-avidity binding to beta-amyloid and increased frequency of 
type 4 allele in late-onset familial Alzheimer disease. Proc Natl 
Acad Sci U S A. Vol. 90. n.º 5. p. 1977-81. 
Suh, Y. H.; Checler, F. 2002. Amyloid precursor protein, presenilins, and 
alpha-synuclein: molecular pathogenesis and pharmacological 
applications in Alzheimer's disease. Pharmacol Rev. Vol. 54. n.º 3. 
p. 469-525. 
Sun, N.; Funke, S. A.; Willbold, D. 2012. A survey of peptides with effective 
therapeutic potential in Alzheimer's disease rodent models or in 
human clinical studies. Mini Rev Med Chem. Vol. 12. n.º 5. p. 388-
98. 
Swahn, B. M.; Kolmodin, K.; Karlstrom, S.; von Berg, S.; Soderman, P.; 
Holenz, J.; Berg, S.; Lindstrom, J.; Sundstrom, M.; Turek, D.; 
Kihlstrom, J.; Slivo, C.; Andersson, L.; Pyring, D.; Rotticci, D.; 
Ohberg, L.; Kers, A.; Bogar, K.; von Kieseritzky, F.; Bergh, M.; 
Olsson, L. L.; Janson, J.; Eketjall, S.; Georgievska, B.; Jeppsson, F.; 
Falting, J. 2012. Design and synthesis of beta-site amyloid 
precursor protein cleaving enzyme (BACE1) inhibitors with in 
vivo brain reduction of beta-amyloid peptides. J Med Chem. Vol. 
55. n.º 21. p. 9346-61. 
 
 
  
 
48 Chapter 2 
 
Szegedi, V.; Fulop, L.; Farkas, T.; Rozsa, E.; Robotka, H.; Kis, Z.; Penke, Z.; 
Horvath, S.; Molnar, Z.; Datki, Z.; Soos, K.; Toldi, J.; Budai, D.; 
Zarandi, M.; Penke, B. 2005. Pentapeptides derived from Abeta 1-
42 protect neurons from the modulatory effect of Abeta fibrils--an 
in vitro and in vivo electrophysiological study. Neurobiol Dis. Vol. 
18. n.º 3. p. 499-508. 
Tjernberg, L. O.; Lilliehook, C.; Callaway, D. J.; Naslund, J.; Hahne, S.; 
Thyberg, J.; Terenius, L.; Nordstedt, C. 1997. Controlling amyloid 
beta-peptide fibril formation with protease-stable ligands. J Biol 
Chem. Vol. 272. n.º 19. p. 12601-5. 
Tjernberg, L. O.; Naslund, J.; Lindqvist, F.; Johansson, J.; Karlstrom, A. R.; 
Thyberg, J.; Terenius, L.; Nordstedt, C. 1996. Arrest of beta-
amyloid fibril formation by a pentapeptide ligand. J Biol Chem. Vol. 
271. n.º 15. p. 8545-8. 
Torchilin, V. P. 1996. Affinity liposomes in vivo: Factors influencing target 
accumulation. Journal of Molecular Recognition. Vol. 9. n.º 5-6. p. 
335-346. 
Torchilin, V. P. 2005. Recent advances with liposomes as pharmaceutical 
carriers. Nat Rev Drug Discov. Vol. 4. n.º 2. p. 145-60. 
Torchilin, V. P.; Omelyanenko, V. G.; Papisov, M. I.; Bogdanov, A. A., Jr.; 
Trubetskoy, V. S.; Herron, J. N.; Gentry, C. A. 1994. Poly(ethylene 
glycol) on the liposome surface: on the mechanism of polymer-
coated liposome longevity. Biochim Biophys Acta. Vol. 1195. n.º 1. 
p. 11-20. 
Torok, M.; Abid, M.; Mhadgut, S. C.; Torok, B. 2006. Organofluorine 
inhibitors of amyloid fibrillogenesis. Biochemistry. Vol. 45. n.º 16. 
p. 5377-5383. 
  
 
Chapter 2 49 
 
van Rooy, I.; Mastrobattista, E.; Storm, G.; Hennink, W. E.; Schiffelers, R. M. 
2011. Comparison of five different targeting ligands to enhance 
accumulation of liposomes into the brain. J Control Release. Vol. 
150. n.º 1. p. 30-6. 
Veronese, F. M. 2001. Peptide and protein PEGylation: a review of 
problems and solutions. Biomaterials. Vol. 22. n.º 5. p. 405-17. 
Vieira, E. P.; Hermel, H.; Mohwald, H. 2003. Change and stabilization of the 
amyloid-beta(1-40) secondary structure by fluorocompounds. 
Biochim Biophys Acta. Vol. 1645. n.º 1. p. 6-14. 
Visser, C. C.; Stevanovic, S.; Voorwinden, L. H.; van Bloois, L.; Gaillard, P. J.; 
Danhof, M.; Crommelin, D. J.; de Boer, A. G. 2005. Targeting 
liposomes with protein drugs to the blood-brain barrier in vitro. 
Eur J Pharm Sci. Vol. 25. n.º 2-3. p. 299-305. 
Vyas, S. P., Sihorkar V. - Advances in liposomal therapeutics. New Delhi: 
CBS Publishers, 2001.  
Walus, L. R.; Pardridge, W. M.; Starzyk, R. M.; Friden, P. M. 1996. Enhanced 
uptake of rsCD4 across the rodent and primate blood-brain 
barrier after conjugation to anti-transferrin receptor antibodies. 
Journal of Pharmacology and Experimental Therapeutics. Vol. 277. 
n.º 2. p. 1067-1075. 
Wang, E.; Obeng-Adjei, N.; Ying, Q.; Meertens, L.; Dragic, T.; Davey, R. A.; 
Ross, S. R. 2008. Mouse mammary tumor virus uses mouse but 
not human transferrin receptor 1 to reach a low pH compartment 
and infect cells. Virology. Vol. 381. n.º 2. p. 230-40. 
Weidemann, A.; Konig, G.; Bunke, D.; Fischer, P.; Salbaum, J. M.; Masters, C. 
L.; Beyreuther, K. 1989. Identification, biogenesis, and localization 
of precursors of Alzheimer's disease A4 amyloid protein. Cell. Vol. 
57. n.º 1. p. 115-26. 
  
 
50 Chapter 2 
 
Wohlfart, S.; Gelperina, S.; Kreuter, J. 2012. Transport of drugs across the 
blood-brain barrier by nanoparticles. J Control Release. Vol. 161. 
n.º 2. p. 264-73. 
Wood, S. J.; MacKenzie, L.; Maleeff, B.; Hurle, M. R.; Wetzel, R. 1996. 
Selective inhibition of Abeta fibril formation. J Biol Chem. Vol. 271. 
n.º 8. p. 4086-92. 
Wood, S. J.; Wetzel, R.; Martin, J. D.; Hurle, M. R. 1995. Prolines and 
amyloidogenicity in fragments of the Alzheimer's peptide 
beta/A4. Biochemistry. Vol. 34. n.º 3. p. 724-30. 
Wu, D.; Pardridge, W. M. 1999. Blood-brain barrier transport of reduced 
folic acid. Pharm Res. Vol. 16. n.º 3. p. 415-9. 
Zambaux, M. F.; Bonneaux, F.; Gref, R.; Dellacherie, E.; Vigneron, C. 1999. 
Preparation and characterization of protein C-loaded PLA 
nanoparticles. J Control Release. Vol. 60. n.º 2-3. p. 179-88. 
Zhang, Y.; Pardridge, W. M. 2001. Rapid transferrin efflux from brain to 
blood across the blood-brain barrier. J Neurochem. Vol. 76. n.º 5. p. 
1597-600.
  
 
Chapter 3 51 
 
 
Chapter 3 
3. Interaction of Aβ peptide with 
charged and nonionic surfactants 
3.1. Introduction 
Evidences support a direct association between the degree of 
dementia of patients that have AD and the concentration of soluble 
aggregates of the Aβ peptide (Clippingdale, 2001; Hardy, 2002; Ladiwala, 
2012). The aggregation process of the Aβ peptide leads to the formation of 
insoluble fibrils, which accumulate in senile plaques, deposits that 
characterize AD (Andreasen, 2002; Suh, 2002). The more abundant 
sequences of the peptide have 40 (~90%), Aβ(1-40), and 42 (~10%), Aβ(1-
42), amino acids (Citron, 1996). The peptide with 42 amino acids is more 
toxic and it is the major component of the neuritic plaques found in AD 
(Evin, 2002; Roher, 1993). The smaller aggregated intermediates, the Aβ 
oligomers, are considered the more toxic species (Hardy, 2002). The 
control and study of Aβ oligomerization is difficult to achieve, because the 
process is fast and is affected by many variables such as solvent 
hydrophobicity, pH, peptide concentration, temperature, ionic strength, 
and interactions with metal ions (Stine, 2003). The studies of Aβ 
interaction with different surfactant molecules and micelles are important 
to better understand the aggregation process of the Aβ peptide. 
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It has been demonstrated that the surfactant sodium dodecyl 
sulfate (SDS) is able to induce, at specific conditions, a non-fibrillar state of 
the peptide (Rangachari, 2007; Tew, 2008). Like other particles or 
molecules, the use of surfactants could provide a standard procedure for 
obtaining oligomeric assemblies of Aβ and for getting new insights into the 
oligomerization process (Ghavami, 2012). The concentration of the 
surfactant in solution determines its effect on Aβ aggregation (Cao, 2007; 
Coles, 1998; Marcinowski, 1998; Rangachari, 2007; Rangachari, 2006; 
Rocha, 2012a; Sabate, 2005; Shao, 1999; Wahlstrom, 2008). The 
interaction mechanism between surfactants and Aβ may well be 
generalized as it has been suggested for the case of globular proteins 
(Otzen, 2011; Otzen, 2010). There is already an indication of identical 
impacts of charged surfactants on the secondary structure of Aβ(1-40) and 
other short peptides (Cao, 2007; Rocha, 2012a; Rocha, 2008; Sabate, 2005; 
Wahlstrom, 2008). Also, both nonionic and zwitterionic surfactants have 
similar outcomes on the aggregation of Aβ(1-40) (Friedman, 2011). 
This chapter relates to the interactions between different charged 
surfactants (CTAC - cetyltrimethylammonium chloride and SDS - sodium 
dodecyl sulphate) and a nonionic surfactant (OG - octyl β-D-
glucopyranoside) with Aβ(1-42). The ionic surfactants were selected in 
order to have micelles with approximately the same shape. The nonionic 
surfactant was chosen because of its purity when compared with other 
nonionic surfactants. 
To characterize their interaction mechanism and to define common 
alternate aggregation pathways different studies were performed. The 
studies were done using different concentrations of the surfactants, below 
and above their critical micelle concentration (CMC) and by characterizing 
the ultra-structure of the aggregates, their binding to thioflavin T (ThT) 
and their secondary structure. 
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3.2. Materials and methods 
 Amyloid-beta peptides 3.2.1.
Aβ(1–40) peptide  (purity 96%, molecular weight (MW) 4329.90) was 
purchased from GenicBio Limited and Aβ(1–42)  peptide (purity > 95%, MW 
4514.14) was purchased from Selleck Chemicals (Figure 3.1). The 
aggregation state and the structure of the peptide are highly dependent on 
the sample batch (Soto, 1995). To improve peptide solubility and 
disaggregate pre-formed agglomerates, the peptide was first dissolved in 
HFIP (1,1,1,3,3,3-hexafluoro-2-propanol, ≥ 99.8%, Sigma-Aldrich) (to 
disrupt intermolecular H-bonds) at 1 mg/mL concentration (Nilsson, 
2004; Rocha, 2009; Sabate, 2005). HFIP was evaporated with nitrogen 
flow and under vacuum.  The peptide film with the Aβ in a monomeric 
structure was dissolved in DMSO (dimethyl sulfoxide for molecular 
biology, ≥ 99.9%, MW 78.13, Sigma-Aldrich) at 9 mg/mL concentration. 
 
 
 
Figure 3.1 – Amino acids of the two Aβ peptides used in this study and their 
secondary structure prediction. The central hydrophobic cluster is 
represented in grey. 
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 Surfactant solutions 3.2.2.
All surfactants were purchased from Sigma-Aldrich.  Stock 
solutions were prepared by dissolving CTAC (cetyltrimethylammonium 
chloride, 25 wt.% sol. in water, MW 320.01), OG (octyl β-D-
glucopyranoside, ≥ 98%, MW 292.37) or SDS (sodium dodecyl sulphate, 
≥98.5%, MW 288.38) (Table 3.1) in Hepes buffer 10 mM, pH 7.4 (HEPES 
hemisodium salt, ≥ 99%, Sigma-Aldrich) or phosphate buffered saline 
(PBS), pH 7.4 (PBS, 10 mM phosphate buffer, 2.7 mM potassium chloride 
and 137 mM sodium chloride, Sigma-Aldrich). The buffers were prepared 
previously with ultrapure water purified with Milli-Q equipment with the 
specific resistance of 18.2 MΩ∙cm.  
 
Table 3.1 – Chemical structure of the surfactants used in the interaction 
studies with Aβ. 
Name Charge Structure 
SDS Anionic 
 
CTAC Cationic 
 
OG Nonionic 
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 Critical micelle concentration 3.2.3.
measurements 
Amphiphiles have two different parts that have different affinity for 
solvents. The part of the molecule that has an affinity for polar solutions, 
such as water, is called hydrophilic. The other part of the molecule, which 
has an affinity for non-polar solvents, such as hydrocarbons, is named 
hydrophobic (Butt, 2006). These molecules are called amphiphilic or 
amphiphiles. An amphiphilic molecule can positioning itself at the air-
water interface with the polar part in contact with water and the non-
polar part facing the air above the surface. Another possible arrangement 
occurs when the amphiphiles are present in high quantities and form 
aggregates in which the hydrophobic portions are oriented within the core 
and the hydrophilic portions are exposed to the aqueous solvent.  Such 
aggregates are called micelles (Figure 3.2). At low concentrations, the 
arrangement on the surface is favored. As the surface becomes crowded 
with surfactant some molecules will arrange into micelles. When the 
surface becomes completely loaded with surfactant and any further 
additions must be arranged as micelles, this concentration is called the 
CMC (Barnes, 2011).   
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Figure 3.2 – Schematic representation of one micelle. 
 
The CMC of surfactants was measured at room temperature in the 
absence and presence of the Aβ peptide (with a constant concentration of 
46 µM) by two techniques: surface tension (OG and CTAC) and 
conductivity (SDS) measurements. The surface tension method was 
carried out by the hanging drop method using an optical contact angle 
system (OCA 15 plus). Below the CMC, the trend of the surface tension 
versus the logarithm of the concentration can be described by the 
Langmuir-Szyszkowski equation (von Szyszkowski, 1908). Above the CMC, 
the surface tension is almost constant, thus this range can be fitted 
linearly. The CMC corresponds to the value at the intersection of both 
curves (Arlt, 2010). Conductivity was measured using a Crison GLP 31 
conductivimeter. Below and above the CMC the trend of the conductivity 
versus the concentration can be described by two linear equations. The 
intersection of this linear fit corresponds to the CMC (Azum, 2008). 
 
Hydrophilic groups 
Hydrophobic groups 
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 Fluorescence measurements and 3.2.4.
Thioflavin T binding assay 
When atoms, molecules, ions and complexes are exposed to light of 
certain wavelength, they undergo a transition from the energetically 
ground state to the excited state. When the molecules return to its ground 
state they release the previously absorbed energy by radiation or in other 
words, the molecules emit photons.  
The light emitted from an excited singlet state or between states of 
the same spin state is called fluorescence. The fluorescence lifetime is very 
short and founded usually in the nanosecond range. The processes that 
occur between the absorption of light and its emission are represented in 
the Jablonski diagram (Figure 3.3). 
 
 
Figure 3.3 - Jablonski Diagram. 
 
In this diagram   ,   ,    are the singlet ground, first and second 
electronic states, respectively. In each of the states of energy, the 
fluorescent substance can have different vibrational energy levels. The 
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lifetime of a fluorophore is the average time since the excitation until the 
return to the ground state. Few molecules in condensed phases have 
internal conversion. It is a quickly relaxation to the lowest vibrational level 
of    and this occurs within 10–12   or less.  On the other hand, the 
fluorescence lifetime is approximated 10–8   and the internal conversion is 
complete before the emission (Lakowicz, 1988). 
ThT is a classic amyloid dye that is commonly used to probe Aβ 
fibril formation because of its strong fluorescence emission upon binding 
to amyloid fibril structures (Nilsson, 2004). It is assumed that the intensity 
of fluorescence is proportional to the quantity of amyloid fibrils (Jameson, 
2012).  
For ThT assays, a  ThT stock solution was prepared by adding 8 mg 
of ThT to 10 mL of either Hepes or PBS buffers (Nilsson, 2004). This 
solution was filtered through a 0.2 μm syringe filter and diluted (1 mL of 
ThT stock solution in 50 mL of buffer) before each measurement (ThT 
working solution). An aliquot of 20 μL of each sample was mixed with 1 
mL of ThT working solution, stirred for 1 min, and the fluorescence 
intensity was measured using a Perkin Elmer LS 50B (Waltham, 
Massachusetts, USA) fluorescence spectrometer, averaging over 60 s. Upon 
binding to amyloid fibrils, the ThT has an excitation maximum at 450 nm 
and enhanced emission at 482 nm. The spectra were subtracted to the 
controls (ThT working solution and surfactants). For kinetic studies, the 
samples containing Aβ and CTAC (0.50 mM and 1.40 mM) or SDS (4.00 mM 
and 14.00 mM) in PBS buffer were diluted and added to ThT working 
solution immediately after preparation leading to the following final 
concentrations: 12.50 μM of Aβ peptide, 62.50 μM and 0.175 mM of CTAC; 
0.50 mM and 1.75 mM of SDS. The samples were placed on a 96-well plate 
(Nunclon Delta Surface) and the fluorescence intensity was measured 
using a Biotek Synergy (Winooski, Vermont, USA) 2 fluorescence 
spectrometer after stirring 30 s at 37 °C every 15 min during 2 days. The 
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measurements were performed with a 420/50 nm excitation filter and a 
485/20 nm emission filter. 
 
 Transmission electron microscopy 3.2.5.
Transmission electron microscopy (TEM) gives real space images, 
including the surface and the internal structures of materials, tissues and 
cells.  
In TEM technique, an electron beam is transmitted through the 
sample under observation (Figure 3.4). The applied intensity depends on 
the thickness of the sample and the concentration of atoms in that sample. 
This technique is used for contrasting a thin specimen with an optically 
opaque fluid. 
 
Source
Condenser Lens
Sample
Objective Lens
Projector Lens
Image
Backfocal Plane
 
Figure 3.4 - Diagram in the area of the objective lens of an electron 
microscope. Adapted from (Cahn, 1996; Hiemenz, 1997). 
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For the ultra-structural studies of the Aβ peptide (100 µM) in the 
absence and presence of the different surfactants at different 
concentrations, 5 μL of each sample was placed on carbon-formvar coated 
200-400 mesh spacing grids (Agar Scientific) and let to adsorb for five 
minutes. The negative staining was performed with 2% filtered aqueous 
solution of uranyl acetate for 45 seconds. After removing the excess of the 
negative staining solution and drying the grids, the samples were 
visualized using a Jeol JEM 1400 electron microscope at 80 kV. 
 
 Fourier-Transform Infrared 3.2.6.
The Fourier-Transform Infrared (FTIR) spectroscopy studies the 
interaction of infrared radiation with the matter, being capable of 
analysing a wide variety of materials: organic or inorganic, solid, liquid or 
gaseous. 
FTIR spectroscopy instrumentation is constituted generally by a 
Michelson interferometer and a computer. The interferometer comprises a 
source of radiation, a beam splitter, a fixed mirror, a moving mirror and 
the detector (Figure 3.5). The laser produces a unique frequency of red 
light which follows the same trajectory of the infrared radiation. There are 
many types of detectors, but the most used are the deuterated triglycine 
sulfate detector (DTGS) and the mercury cadmium telluride detector 
(MCT). A computer performs the conversion of the interferogram into the 
representation in the frequency domain, using the Fourier transform. 
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Figure 3.5 - Schematic representation of a FTIR equipment. Adapted from 
(Silva, 2007). 
 
This technique is useful for the identification of different chemical 
bonds in molecules, as each specific chemical bond absorbs incident light 
at a specific wavelength. FTIR measures the frequency of the vibrations of 
chemical bonds between atoms when excitation occurs. The absorption 
frequencies of radiation depend on the functional groups present and the 
configuration of the atoms in the molecule. When a given bond absorbs 
radiation, it will become excited, and consequently the frequency of its 
molecular vibration will increase. The infrared vibrational spectrum of a 
molecule consists of a sequence of bands, each of which results from a 
transition between pairs of vibrational levels related to the ground 
electronic state.  
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FTIR Spectroscopy has qualitative and quantitative applications. Its 
qualitative applications rely on the fact that pure compounds possess a 
very characteristic FTIR spectrum. Therefore, an unknown material can be 
identified by comparing its FTIR spectrum to spectra of known 
compounds. The technique is also used to identify functional groups of a 
sample and to control the quality of a specific material by comparison with 
a standard material. Besides the qualitative information, this method also 
gives quantitative information. All quantitative applications of FTIR 
Spectroscopy lay on the Lambert-Beer law (the intensity of the 
transmitted radiation is inversely proportional to the concentration of the 
sample). 
Attenuated total reflectance (ATR) accessories are especially useful 
for obtaining infrared spectra of difficult samples that cannot be readily 
examined by the normal transmission method. They are suitable for 
studying thick or highly absorbing solid and liquid materials, including 
films, coatings, powders, threads, adhesives, polymers, and aqueous 
samples. ATR requires little or no sample preparation for most samples 
and is one of the most versatile sampling techniques. 
ATR-FTIR spectra were recorded with a Bruker Alpha-P 
spectrophotometer. The measurements were performed using the same 
solutions used in the TEM experiments and the buffer spectrum was 
subtracted. All spectra were recorded by averaging 200 scans at a 
resolution of 4 cm-1. 
 
 Theoretical kinetic model 3.2.7.
The theoretical kinetic model created by Hellstrand et al. 
(Hellstrand, 2010), which describes protein aggregation is a tool to find 
the time at half completion of aggregation process, t1/2, that was estimated 
by fitting sigmoidal function (Equation 3.1) to each parameter. 
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 (3.1) 
 
The fitted parameters are t1/2, the elongation rate constant, k, the 
amplitude, A, and the baseline before aggregation, F0. The lag time, tlag, is 
the interception between the time axis and the tangent with slope k from 
the midpoint of the fitted sigmoidal curve. By this definition, tlag was 
calculated from the fitted parameter as described by equation 3.2. 
 
(3.2) 
 
 
The kinetic data from ThT assay was fitted by the model. 
 
3.3. Results and Discussion 
 Interaction of amyloid-beta with 3.3.1.
surfactants  
The aggregation of Aβ peptides was studied in the presence of 
surfactants by ultra-structural analysis at a peptide concentration of 100 
μM and surfactant concentrations below and above the CMC. The CMC 
values for the surfactants at the given buffer conditions used in the 
experiments were determined by surface tension and conductivity and are 
listed in Table 3.2. In the case of charged surfactants, the CMC decreases 
drastically in the presence of salts. 
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Table 3.2 - Properties of the surfactants that were used in this study. 
Surfactant 
CMC4 in 
Hepes5 (mM) 
CMC in PBS6 
(mM) 
Size of the 
micelle (nm) 
Shape of 
the micelle 
CTAC1 0.9 ± 0.2 0.19 ± 0.02 4.8 spherical 
SDS2 6.9 ± 0.3 1.4 ± 0.2 4.8 spherical 
OG3 22.4 ± 0.1 22.2 ± 0.5 
R = 1.3; 
L = 9.6 
cylinder 
1cetyltrimethylammonium chloride;  
2sodium dodecyl sulphate; 
3octyl β-D-glucopyranoside; 
4critical micelle concentration; 
510 mM sodium HEPES buffer, pH 7.4; 
6phosphate buffered saline, 10 mM phosphate buffer, 2.7 mM potassium chloride and 137 mM sodium chloride, 
pH 7.4;  
For OG, R is the radius of the cylinder, and L is its length. 
 
 
Also, it was verified that charged and non-charged surfactants, in 
Hepes buffer, in the presence Aβ(1-40) monomers present different 
behaviors. The presence of Aβ(1-40) does not change the CMC of charged 
surfactants, the SDS maintains its CMC at 6.4 ± 0.3 mM and CTAC presents 
a CMC of 0.8 ± 0.2 mM. The CMC value of the nonionic amphiphile (OG), on 
the other hand, significantly increases from 22 to 28.2 ± 0.9 mM. This 
variation was statistically significant as determined by t-Student test (P < 
0.01). Micelle formation is driven by the hydrophobic effect and the 
interactions between nonionic surfactant monomers are usually stronger 
than that between ionic monomers due to the lack of electrostatic 
repulsion of the polar heads. The increase of the OG CMC induced by Aβ(1-
40) indicates that the surfactant–peptide interactions are favorable enough 
to stabilize the non-ionic monomers in aqueous solutions. In the case of 
the ionic surfactants, the number of sequestered monomers by the peptide 
is most likely too low to be detected by the techniques used to determine 
the CMC.  
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The ultra-structural analysis shows that both the cationic 
surfactant (CTAC) and the anionic surfactant (SDS) promote, in Hepes 
buffer and at concentrations below the CMC, the aggregation of Aβ(1-42). In 
these solution conditions, the surfactants lead to the formation of amyloid-
like, unbranched fibrils similar to that observed for the peptide alone 
(Figure 3.6). These fibrils have an average diameter of 21 nm. The 
negative-staining agent (uranyl acetate) is estimated to increase by 
approximately 1 nm the size of the fibrils. The obtained values for Aβ(1-42) 
fibril size are concordant with that presented in the literature (Chen, 
2005; Klement, 2007). In the case of Aβ(1-42) incubated with the charged 
surfactants at micellar concentrations (concentration above the CMC), 
only small aggregates are observed, indicating that they inhibit the Aβ 
fibrillogenesis. The aggregates were similar to that observed for the 
peptide in the initial state (Figure 3.6, time = 0 h). Comparable results 
were obtained for surfactant micellar concentrations in the presence of 
salt (PBS buffer). 
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Figure 3.6 - TEM images of the effect of the surfactants CTAC and SDS on 
Aβ(1–42) aggregation. The Aβ(1-42) concentration was 100 μM. The samples 
were incubated for 6 days at 37 °C in the presence or absence of surfactants 
in Hepes or PBS buffer. The surfactant concentrations were below and 
above the CMC (CTAC 0.50 mM and 1.40 mM; SDS 4.00 mM and 14.00 mM) in 
Hepes buffer and above the CMC (CTAC - 1.40 mM; SDS – 14.00 mM) in PBS 
buffer. The scale bar corresponds to 400 nm.  
 
  
 
Chapter 3 67 
 
A significant binding to ThT is observed for Aβ(1-42) incubated alone. 
The fluorescence intensity at 450 nm, which is the characteristic excitation 
maximum observed upon ThT binding, increased after 1 day incubation 
time at 37 °C; for the samples containing OG, the non-ionic surfactant, the 
fluorescence intensity of ThT was higher than that observed for Aβ alone 
(Figure 3.7), whereas for the mixtures of Aβ(1-42) and charged micelles the 
intensity of fluorescence was low and maintained close to that of the Aβ 
starting point. These results reveal that charged micelles show significant 
inhibition of Aβ fibril formation. 
 
 
 
Figure 3.7 - The effect of surfactants on Aβ(1–42) fibril content as monitored 
by ThT fluorescence. The Aβ(1-42) concentration was 100 μM. The samples 
were incubated at 37 °C in the presence or absence of surfactants in 10 mM 
Hepes buffer, pH 7.4. All the surfactant concentrations were above the CMC 
(CTAC – 1.40 mM; SDS - 14.00 mM; OG – 29.80 mM). 
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The Aβ(1-42) aggregation kinetics in surfactant environment was 
studied for SDS and CTAC at two different concentrations close to their 
CMC by means of ThT fluorescence (Figure 3.8). The Aβ(1-42) concentration 
was kept at 12.5 μM, which was significantly above the critical 
concentration below which fibrils cannot form (0.2 μM) (Hellstrand, 
2010). The lag time, tlag, and the time at half completion of the aggregation 
process, t1/2, were obtained by fitting a sigmoidal function to each kinetic 
trace according to the model presented by Hellstrand et al. (Hellstrand, 
2010). Both parameters were affected by the presence of surfactants and 
were significantly longer for Aβ(1-42) incubated with SDS than for Aβ(1-42) 
alone (Figure 3.8). Also, the ThT fluorescence plateau decreased. 
The increase of surfactant concentrations slowed down the fibril 
formation and the higher value of t1/2 was obtained for the highest 
concentrations of SDS (1.75 mM). In the case of CTAC at 0.18 mM, the 
fluorescence intensity was below the noise level, and thus it was not 
possible to calculate the tlag and t1/2, suggesting a stronger inhibitory action.  
The t1/2 of the aggregation process was approximately four times 
higher in the case of the sample with SDS 1.75 mM when compared with 
the peptide alone. SDS at 0.50 mM induced an inhibitory effect of 0.37 days 
(approximately 9 h). 
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Figure 3.8 – Concentration dependence of charged surfactants in Aβ(1–42) 
fibril formation in PBS. A) and B) Aggregation kinetics of Aβ(1–42) (100 μM) 
in the presence of two different surfactant concentration close to the CMC.  
C) and D) Fitting of equation 3.1 to Aβ(1–42) kinetic points, with data showed 
as points and the fitted curve (solid line). The values for t1/2 were obtained 
by the fit and tlag was achieved by the equation 3.2. 
 
52.50 µM 
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Aβ alone Aβ alone 
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The nonionic surfactant OG promoted the Aβ(1-42) aggregation both 
at submicellar and micellar concentrations (and either in Hepes or PBS 
buffer) (Figure 3.9). The fibrils had a different morphology and to confirm 
if they were of the amyloid type, their secondary structure was analyzed 
by ATR-FTIR spectroscopy. The spectra of Aβ(1-42) in the presence of OG 
below and above the CMC in PBS buffer were similar to that of the Aβ(1-42) 
incubated alone (Figure 3.9). These spectra are characterized by a band in 
the Amide I region with a maximum intensity at 1624 cm-1, which is 
assigned to β-sheet-rich amyloid fibrils (Cerf, 2009). 
The results indicate that charged surfactant monomers interact 
with Aβ(1-42) through electrostatic interactions. This will cause the exposure 
of peptide hydrophobic parts that will promote hydrophobic interactions 
between peptide molecules, which eventually lead to aggregation (Figure 
3.10). Charged micelles will also interact electrostatically with Aβ(1-42). In 
this case, however, the concentration of charged micelles is high enough 
for surrounding the Aβ(1-42) peptide molecules inducing consequently an 
electrostatic repulsion between the peptide-micelle structures (Figure 
3.10) favoring a non-aggregated state. This study confirms the 
fibrillization-inhibiting effect of charged micelles. 
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Figure 3.9 – Effect of non-charged surfactants in Aβ(1–42) aggregation. TEM 
images and FTIR spectra of the Aβ(1–42) in the presence of monomers and 
micelles of OG surfactant (respectively 10.00 mM and 29.80 mM). For TEM 
analysis, the samples were incubated for 2 days at 37 °C in the presence of 
surfactant in 10 mM Hepes buffer or 10 mM PBS buffer, pH 7.4. The scale 
bar corresponds to 400 nm. FTIR spectra were obtained for the peptide 
incubated for 2 days at 37 °C in PBS buffer, 137 mM NaCl, pH 7.4. 
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Figure 3.10 – Schematic representation of the possible mechanism for the 
interactions of Aβ(1-42) with the charged and nonionic surfactants at 
monomeric or micelle concentrations. Experimental data show that the 
peptide in the presence of charged micelles does not aggregate, whereas in 
the presence of monomers it aggregates. The Aβ in the presence of nonionic 
monomers and micelles reaches complete aggregation. 
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Other charged NPs were shown to have also a fibrillization-
inhibiting effect (Liao, 2012; Saraiva, 2010a; Saraiva, 2010b). Liao et al. 
used bare and carboxyl conjugated gold nanoparticles (AuNPs) to inhibit 
the formation of fragmented fibrils and spherical oligomers. They showed 
that the negative surface potential of AuNPs is essential for the 
interactions between the peptide (Aβ(1-40)) and the AuNPs and as a result 
of this interaction the peptide aggregation is inhibited (Liao, 2012). 
Saraiva et al. demonstrated that fluorinated NPs promote an increase in 
the α-helical content of the Aβ(1-42) peptide and have an anti-oligomeric 
effect (Saraiva, 2010a). Sulfonated and sulfated polystyrene NPs, which 
are negatively charged polymeric nanostructures, also affected the 
conformation of Aβ and induced an unordered state, delaying the peptide 
oligomerization (Saraiva, 2010b). 
The effect of non-charged surfactants below the CMC on Aβ(1-42) 
may be explained by the presence of more hydrophobic molecules 
(monomers) in solution that favor hydrophobic interactions (Figure 3.10). 
The OG micelles in solution behave as inert bodies and act as nuclei of 
aggregation. 
Other previous studies with Aβ(1-40) fragment (46 μM) in aqueous 
buffer, pH 7.4, suggest that the peptide shows a low content of β-sheet 
structures in the presence of micelles of charged surfactants, SDS and 
CTAC (Rocha, 2012b). On the contrary, the presence of these surfactants 
below the CMC induces a β-sheet conformation. The presence of OG at 
concentrations above the CMC leads to a β-sheet conformation as opposed 
to what is observed in the case of charged micelles (Rocha, 2012b). The 
hypothesis is that Aβ(1-40) interacts with uncharged OG monomers through 
hydrophobic interactions. 
A dual effect of cationic surfactants (alkylammonium bromides) on 
Aβ(1-40) structure has also been reported, as the alkylammonium bromide 
surfactants favored the Aβ fibril formation at concentrations below the 
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CMC and delay the fibril formation at concentrations above their CMC 
(Sabate, 2005). Cao et al. found that cationic Gemini surfactant 
hexamethylene-1,6-bis (dodecyl dimethylammonium bromide) 
(C12C6C12Br2) micelles delay the formation of Aβ(1-40) fibrils. The 
interaction of charged and zwitterionic surfactants with the Aβ-peptide 
fragment (1-28) demonstrated that the promotion and stabilization of α-
helix secondary structure are highly dependent on the surface charge of 
the micelles (Marcinowski, 1998). The aggregation kinetics of the peptide 
is also significantly affected by the presence of salt ions (Klement, 2007). 
Ions may concentrate non-specifically in the vicinity of oppositely charged 
peptide groups, increasing the apparent dielectric constant of water and 
promoting stronger electrostatic interactions between peptide–peptide 
molecules. Alternatively, ions may interact specifically with charged or 
polar chemical groups of the peptide chain (Baldwin, 1996; RiesKautt, 
1997). 
The aggregation mechanism of Aβ peptides is still very much 
debatable because studies performed under different conditions lead to 
different proposed mechanisms. The fast aggregation kinetics and 
different aggregation stages of peptide samples are obstacles for uniform 
and generalized studies. The use of surfactants may contribute to a better 
understanding of the peptide aggregation and above all may allow the 
study of the fibrillization process at concentrations that can easily be 
reproduced. 
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CHAPTER 4 
4. Effect of fluorinated peptides on Aβ 
assembly  
4.1. Introduction 
Increasing evidences suggest that soluble Aβ oligomers might be 
critical for the onset of AD (Gong, 2003; Kayed, 2003; Klein, 2001; 
Shankar, 2007; Shankar, 2008). In the view of this hypothesis, a possible 
strategy to treat the disease is to inhibit the early stages of Aβ aggregation 
(Hardy, 2002). The two hydrophobic cores of Aβ peptide, the residues 17-
21 and 30-42, have been associated to its aggregation process (Hilbich, 
1992; Jarrett, 1993). Based on the 17-21 hydrophobic residues, LVFFA, of 
Aβ Soto et al. designed a peptide that binds to the full length Aβ and 
prevents its aggregation (Soto, 1996). This inhibitor has a similar degree 
of hydrophobicity, but has a very low propensity to adopt a β-sheet 
conformation due to the presence of a proline residue. Valine, that it is 
considered a key residue for the β-sheet formation, was replaced by 
proline, an amino acid thermodynamically unable to fit in the β-sheet 
structure (Chou, 1978; Soto, 1996; Wood, 1995). The peptide LPFFD, 
referred to as iAβ5, binds to Aβ and blocks the interaction between Aβ 
molecules, inhibiting the formation of the oligomeric β-sheet 
conformation, which is the precursor of the fibrils. Certain fluorinated 
compounds have also been proposed as inhibitors of Aβ aggregation 
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(Adamski-Werner, 2004; Torok, 2006; Vieira, 2003). Fluorinated solvents 
such as hexafluoroisopropanol induce an α-helix structure in Aβ peptide. A 
similar effect is observed when Aβ interacts with 
poly(tetrafluoroethylene) surfaces or fluorinated nanoparticles 
(Giacomelli, 2005; Rocha, 2008; Saraiva, 2010). Since the hydrogenated 
analogues of the NPs were not able to prevent the amyloid fibril formation, 
it has been postulated that fluorine atoms play an important role on the 
inhibition of Aβ aggregation. Thus, peptides containing fluorinated amino 
acids were synthetized and their influence on Aβ oligomerization was 
studied. The fluorinated peptides are also based on the hydrophobic 
central residues of Aβ(1-42) 17-21 (LVFFA) and on the iAβ5 beta-sheet 
breaker peptide. The fluorinated sequences were covalently linked to PEG 
to increase their solubility (Figure 4.1). The coupling iAβ5 to PEG does not 
compromise its affinity to Aβ or the iAβ5 beta-sheet breaker activity 
(Rocha, 2009). PEG has additionally very low toxicity and is known to 
reduce protein degradation by proteolytic enzymes (Veronese, 2001). The 
use of non-natural residues such as fluorinated amino acids is also known 
to efficiently improve the stability of peptides or proteins against 
enzymatic degradation (Buer, 2012). The conjugates of fluorinated 
peptide-PEG were characterized by matrix-assisted laser 
desorption/ionization mass spectrometry. The kinetics of the Aβ(1-42) 
aggregation, in the presence and in the absence of the conjugates, was 
evaluated by the ThT assay and the data were fitted using the 
crystallization-like model recently described by Crespo et. al. (Crespo, 
2012). The ultrastructure characterization of the Aβ aggregates was 
performed by transmission electron microscopy. 
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4.2. Material and Methods 
4.2.1. Synthesis of conjugates of fluorinated 
peptides and polyethylene glycol 
 The conjugates were prepared by the solid-phase supported 
strategy. Direct synthesis of the conjugate was performed applying a resin 
comprising a cleavable PEG spacer. Automated stepwise amino acid 
attachment was applied, following standard Fmoc-protocols. TentaGel PEG 
Attached Peptide resin (loading: 0.24 mmol/g; PDI = 1.06 [GPC (THF, 
calibrated against linear PEG standards, PSS, Germany)] was purchased 
from Rapp, Polymere GmbH. Fmoc amino acids derivatives (Fmoc-
phenylalanine OH, Fmoc-leucine OH, Fmoc-aspartic acid OH, Fmoc-valine 
OH, Fmoc-4;4;4-trifluoro-DL-valine, Fmoc-3;4;5-trifluoro-L-phenylalanine 
and Fmoc-trans-4-Fluoro-L-proline) were used as purchased from 
AnaSpec.  The sequences of the fluorinated peptides are shown in Figure 
4.1. After the synthesis, the conjugates were dissolved in distilled water 
with 1% guanidinium hydrochloride and the pH was adjusted to 7 
with sodium hydroxide 1 M. The samples were dialyzed against ultrapure 
water using a regenerate cellulose membrane (MWCO 1000 Da) for 4 days 
followed by lyophilization. 
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Figure 4.1 - Sequences of the fluorinated peptides conjugated to PEG used in 
this study. The chemical structure of the fluorinated amino acids is also 
shown (source: PubChem of the National Center for Biotechnology 
Information) 
 
4.2.2. Stock solutions of amyloid-beta 
peptide 
Aβ(1-42) (amyloid-β peptide 1-42, purity > 95.22%, MW 4514.14, 
Selleck Chemicals) was prepared as is described in the Chapter 3, Section 
3.1.1. 
  
Amyloid-beta peptide 
Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-
Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala 
Conjugates 
Leu-FluoroPro-Phe-Phe-Asp-PEG (LPfFFD-PEG) 
 
Leu-Val-FluoroPhe-Phe-Asp-PEG (LVFfFD-PEG) 
 
Leu-FluoroVal-Phe-Phe-Asp-PEG (LVfFFD-PEG) 
 
 
Fluorinated amino acids 
   
3,4,5 – trifluorophenylalanine          4-fluoroproline   4,4,4-Trifluorovaline 
 
  
n!
n!
n!
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4.2.3. Matrix-assisted laser 
desorption/ionization mass spectrometry  
The ionization technique called Matrix-assisted laser 
desorption/ionization (MALDI), allows the evaluation of biomolecules, 
such as peptides and large organic molecules. When conventional 
ionization methods are used, these molecules tend to be fragile and 
fragment. MALDI is used in mass spectrometry procedures. MALDI is a 
two-step process. In the first one, the matrix material deeply absorbs the 
ultraviolet (UV) laser beam, which starts desorption of the upper layer (~1 
μm). In the second step, the molecules are protonated or deprotonated. 
The most common type of mass spectrometer used with MALDI is the TOF 
(time-of-flight mass spectrometer), primarily because its wide mass range. 
In addition the combination of MALDI and TOF is suitable due the 
individual “shots” by the pulsed laser instead of operating continuously. 
MALDI-TOF instrument is capable of reflecting ions using an electric field, 
which double the ion path and increasing the resolution. 
MALDI-TOF measurements were performed in a Voyager-DE STR 
BioSpectrometry Workstation MALDI-TOF mass spectrometer (Perceptive 
Biosystems, Inc., Framingham, MA, USA) at an acceleration voltage of 20 
kV. The fluorinated peptide-PEG conjugates were dissolved in 0.1% TFA in 
acetonitrile–water (1:1, v/v) at a concentration of 0.1 mg/mL. One 
microliter of the analyte solution was mixed with l µL of alpha-cyano-4-
hydroxycinnamic acid matrix solution consisting of 10 mg of matrix 
dissolved in 1 mL of 0.1% trifluoroacetic acid (TFA) in acetonitrile–water 
(1:1, v/v). From the resulting mixture, 1 µL was applied to the sample 
plate. Samples were air-dried at room temperature (RT) (25 °C). Each 
spectrum is a mean of 250 laser shots. 
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4.2.4. Thioflavin T binding assay  
For kinetic studies, Aβ(1-42) peptide (12.5 μM) was incubated at 37 
°C in 96 well plates (Nunclon Delta Surface) with the fluorinated peptide-
PEG conjugates (250 μM) in the presence of ThT (0.7 mg/mL) in PBS 
buffer. ThT solution was filtered using 0.2 μm syringe filter before adding 
to the Aβ samples. The fibrils conjugated with ThT have the excitation 
maximum at 450 nm and enhanced emission at 482 nm (LeVine, 1993). 
The fluorescence intensity was measured every 30 minutes during 24 
hours using a Biotek Synergy 2 fluorescence spectrometer with the 
excitation filter 420/50 nm and the emission filter 485/20 nm. 
 
4.2.5. Theoretical Crystallization-Like 
Model  
The Crystallization-Like Model (CLM) is a generic two-parameter 
model that describes protein aggregation kinetics by a sequence of 
nucleation and growth steps. The CLM is represented by the following 
equation, in which α represents the normalized fraction of amyloid protein 
converted into fibrils (Equation 4.1). 
 
                                          (4.1) 
 
 
and ka and kb are the growth and the nucleation-to-growth rate constants. 
The two parameters are related with the time required to reach half of the 
total fibril conversion (t50) and with the aggregation rate (v50) given the 
slope of the (t) curve at that instant.  
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4.2.6. Transmission electron microscopy  
For ultra-structural studies, Aβ(1-42) peptide (100 μM) was 
incubated at 37 °C with each of the fluorinated peptide-PEG conjugates (2 
mM) in PBS buffer (10 mM, pH 7.4), for 48 hours. An aliquot of each 
sample (5 μL) was placed on carbon-formvar coated 200-400 mesh 
spacing grids and let to adsorb for five minutes. The negative staining was 
performed with 2% filtered aqueous solution of uranyl acetate for 45 
seconds. The grids were visualized using a Jeol JEM 1400 electron 
microscope at 80 kV. 
 
4.2.7. Toxicity assay 
Porcine brain capillary endothelial cells (PBCECs) were incubated 
in Plating-Medium - Earls Medium 199 supplemented with L-Glutamine 
(0.7 mM),  penicillin/streptomycin (1%), gentamicin (1%) and new-born 
calf serum, (all the compounds were purchased at Biochrom) - in a 96 well 
plate (Corning) previously coated with Collagen G (Biochrom). After 48 
hours incubation at 37 °C, the culture medium was replaced. Normally, 
apparent confluence of the monolayers was reached after 4 days 
(approximately 6-8 x104 cells per well). At day 4 the medium was replaced 
by a solution of KRB (Krebs Ringer buffer) composed by NaCl (sodium 
chloride p. A., Mw 58.44, AppliChem), KCl (potassium chloride, Mw 74.56, 
AppliChem), H2KO4P (potassium dihydrogen phosphate p.A., Mw 136.09, 
AppliChem), HEPES (hepes puffedran ≥ 99.5%, p.A., Mw 238.31, ROTH), D-
Glucose (D(+)-glucose anhydrous for biochemistry, Mw 180.16, MERCK), 
MgCl2.6H2O (magnesium chloride hexahydrate p.A., Mw 203.30, 
AppliChem) and CaCl2.2H2O (calcium chloride dehydrate p.A., Mw 147.02, 
AppliChem) and fluorinated peptide-PEG conjugate at different 
concentrations.. 
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The peptide was incubated with the cells for 2 hours at 37 °C. Cells 
without peptides and lysed cells with 1% Triton were used as, 
respectively, negative and positive controls. After removal of the peptide 
suspension by aspiration, the cells were incubated with Alamar Blue 
reagent 40:1 (water:Alamar Blue – v/v). Fluorescence was detected with a 
Fluoroskan Ascent (Labsystems) (excitation – 530 nm; emission – 590 
nm). 
 
4.3. Results  
4.3.1. Fluorinated peptide-PEG conjugates  
The fluorinated sequences conjugated to PEG were analysed by 
MALDI-TOF-MS. The spectrum of LPfFFD-PEG is depicted as 
representative of the results acquired for the conjugates and shows the 
typical distribution of the polymer PEG with the characteristic repeat unit 
of 44.1 ± 0.5 Da, which could be assigned to the ethylene oxide (EO) 
monomer of the PEG (Figure 4.2). The experimentally found signal at m/z 
3694.8, for example, can be assigned to [M+K] = 3692.3 Da by assuming a 
M[EO] of 44.05 Da, n = 68 units, a mass of the peptide of M[peptide] = 655.8 Da, 
a mass of the polymer end groups (1 H = 1 Da) and the mass of a 
potassium counter ion (M[counter ion] = 39.1). 
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Figure 4.2 - MALDI-TOF-MS of LPfFFD-PEG conjugate. 
 
4.3.2. Impact of the peptide-PEG conjugates 
on Aβ(1-42) fibrillization   
The aggregation kinetics of Aβ(1-42) incubated at 37 °C with LPfFFD-
PEG, LVFfFD-PEG and LVfFFD-PEG was evaluated by ThT binding assay 
(Figure 4.3). The molar ratio of Aβ(1-42) and conjugates was 1:20. At 15 
minutes incubation time, the ThT fluorescence intensity is low for all 
samples, which indicates low content of amyloid fibrils. After two hours, a 
large increase in the fluorescence intensity is observed for Aβ(1-42) alone 
and for Aβ(1-42):LPfFFD-PEG samples, reaching the maximum at 4 hours 
incubation time (the fluorescence intensities were normalized to that of 
Aβ(1-42) incubated with ThT at 37 °C for 24 hours). The fluorescence of ThT 
in the presence of Aβ(1-42) and LVFfFD-PEG showed only a moderated 
increase (53%) after 4 hours, whereas that of the sample Aβ(1-42):LVfFFD-
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PEG remained low (15%). The conjugates in the absence of Aβ(1-42) do not 
induce any change in the fluorescence signal of ThT. 
 
 
Figure 4.3 - Fluorescence intensity of ThT in Aβ(1-42) samples containing 
fluorinated peptide-PEG conjugates and incubated at 37 °C. The 
fluorescence signal was normalized to the maximum intensity of the sample 
of Aβ(1-42) without conjugates.  
 
 
The kinetic data were fitted according to the recently proposed 
CLM model (Figure 4.4). The t50 and the v50 were obtained by fitting a 
sigmoidal function to each kinetic trace according to the CLM (Table 4.1) 
(Crespo, 2012). In the case of sigmoidal-type aggregation kinetics such as 
those represented in Figure 4.4, v50 is solely dictated by the growth rate 
constant ka. The parameter v50 did not change significantly in the presence 
of the conjugates. A marked increase of the value of t50 is, however, evident 
for the LVFfFD-PEG and LVfFFD-PEG, which can be explained by the CLM 
as the result of either nucleation-prevention or solubility-change effects. 
The later hypothesis is discarded by the fact that the maximum 
fluorescence signal did not show significant variation in the presence of 
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conjugates (results not shown here). Therefore, the increased induction 
times to the inhibition of the nucleation step is ascribe as a possible 
consequence of the stabilization of the Aβ molecule by the conjugates. The 
higher value of the induction time t50 is obtained for the conjugate 
containing the fluorinated valine (LVfFFD-PEG), suggesting a stronger 
inhibitory effect in this case. Inhibitors of the amyloid fibril formation may 
act upon the initial assembly of macromolecules forming the stable nuclei 
(nucleation step) or block the subsequent addition of new growth units 
(growth step) (Crespo, 2012). A third way of action involves the alteration 
of the thermodynamic solubility of the polypeptide. This alternative is 
more unlikely to result in vivo since cell and tissue media are in general 
buffered against non-specific interactions. For example, comparing the 
effect of a well-known and well accepted β-sheet breaker peptide, iAβ5 
(LPFFD) on Aβ(1-42) aggregation, a similar effect was obtained by the 
LVfFFD-PEG conjugate (3.1 hours) (Table 4.1). At the same molar ratio and 
with the same Aβ(1-42) batch, the reduction of the aggregation time of Aβ(1-
42)  is similar for iAβ5 and LVfFFD-PEG. The conjugate containing 
fluorinated phenylalanine (LVFfFD-PEG) induced an inhibitory effect of 1.5 
hours and the LPfFFD-PEG did not inhibit the Aβ(1-42) aggregation. 
The Aβ(1-42):conjugate molar ratio of 1:5 did not significantly change 
the aggregation parameters of Aβ, which indicates that there is a threshold 
concentration for the Aβ-conjugate interaction. 
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Figure 4.4 - Numerical fit of Eq. 4.1 to the normalized conversion of Aβ(1–42) 
peptide incubated in the presence of conjugates at 37 °C in PBS buffer, 
monitored by ThT fluorescence. The Aβ(1-42) concentration was keep 
constant at 12.5 μM and the molar ratio of Aβ(1–42):conjugates was 1:20. The 
aggregation rate (v50) was obtained by fitting a sigmoidal function to each 
kinetic trace according to the Eq. 4.1. 
 
 
Table 4.1 - Time required to reach half of the total fibril conversion (t50) 
and delay in the aggregation of the Aβ(1–42) in the absence and presence of 
fluorinated peptide conjugates and LPFFD peptide. 
 t50 (hours) Delay in aggregation (hours) 
Aβ(1–42) alone 2.1 - 
Aβ(1–42) and LPfFFD-PEG 2.4 0.2 
Aβ(1–42) and LVFfFD-PEG 3.6 1.5 
Aβ(1–42) and LVfFFD-PEG 5.2 3.1 
Aβ(1–42) and iAβ5 5.4 3.3 
 
  
  
 
Chapter 4 93 
 
This assays evidenced that two of the fluorinated peptides (LVFfFD-
PEG and LVfFFD-PEG) are able to delay the aggregation of the Aβ(1-42). 
Hydrophobic interactions and H-bonding among side-chain groups are the 
two major driving forces that control protein aggregation (Petkova, 2002). 
A large amount of evidence indicates that there are three distinct regions 
within the Aβ(1-42) sequence that might be involved in its aggregation: the 
central hydrophobic cluster correspondent to the 17-21 region, the 23-28 
residues and the hydrophobic C-terminus (Antzutkin, 2003; Pike, 1995; 
Torok, 2002). Considering that fluorine atoms increase the hydrophobicity 
of the sequences, it is expected that they would interact with hydrophobic 
regions of Aβ(1-42) to be segregated away from the water. This interaction 
might contribute to the prevention of Aβ molecules with each other, 
inhibiting thus their aggregation. The PEG molecules linked to the 
fluorinated peptides can also contribute to the interaction of the 
conjugates with Aβ(1-42). Previously Rocha et al. have showed that the 
pegylation of a beta-sheet breaker peptide did not significantly change its 
binding to Aβ(1-42) (Rocha, 2009). PEG is described to bind to proteins such 
as albumin and lysozyme even in solution with an ionic strength similar to 
the physiological conditions (Wu, 2013). In the case of the fluorinated 
peptide-PEG conjugates, their effect on Aβ(1-42) cannot be simply explained 
by the PEG-Aβ interaction since the three conjugates show different 
outcomes.    
TEM analysis shows that Aβ(1-42) incubation at 37 °C for 48 hours 
resulted in amyloid-like, unbranched fibrils (Figure 4.5). Aβ(1-42) also forms 
fibrils in the presence of the conjugates (or  iAβ5), although the samples 
containing LVFfFD-PEG and LVfFFD-PEG show also small aggregates. This 
analysis demonstrates that the bioconjugates and the beta-sheet breaker 
iAβ5 only delay the Aβ(1-42) fibrillogenesis. 
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Figure 4.5 - TEM images of the Aβ(1–42) in the absence and presence of 
fluorinated peptide conjugates and LPFFD peptide. Aβ(1–42) was incubated at 
37 °C in the presence of the conjugates (molar ratio 1:20) in 10 mM PBS 
buffer, pH 7.4. A) Aβ(1–42) alone at 0 hours incubation, B) Aβ(1–42) alone at 48 
hours incubation, C) Aβ(1–42) in the presence of LPFFD peptide at 48 hours 
incubation, 1) Aβ(1–42) in the presence of LPfFFD-PEG at 48 hours incubation, 
2) Aβ(1–42) in the presence of LVFfFD-PEG at 48 hours incubation and 3) Aβ(1–
42) in the presence of LVfFFD-PEG at 48 hours incubation. The scale bar 
corresponds to 200 nm. 
 
The fluorinated amino acids of the conjugates may play an 
important role in delaying the Aβ(1-42) aggregation by interacting with the 
hydrophobic residues of the Aβ and preventing its interaction with other 
Aβ molecules. There is also a geometric preference for the interaction 
between C-F bond and the side-chain amides of glutamine (E) 15 and 
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asparagine (N) 27 residues (Muller, 2007). Therefore, the fluorine atoms 
might be able to interact with the two stretches of Aβ hydrophobic 
residues responsible for its oligomerization (17-21 and 30–42 residues) 
and/or with residues in their vicinity by exploiting the same interaction as 
in Aβ(1-42) assembly. A conformational tightened state is produced by the 
interplay of ionic and hydrophobic groups of both peptide and the 
conjugates. 
Ferrão-Gonzales et al. showed that (1-anilino-8-naphthalene 
sulfonate)-derived molecules inhibit Aβ aggregation due to their dual 
nature provided by hydrophobic regions and charged groups (Ferrao-
Gonzales, 2005). Vieira et al. demonstrated the effectiveness of different 
fluorinated alcohols for the β-to-α refolding process of Aβ(1-40) (Vieira, 
2003). The observed effect was interpreted as a result of alterations of the 
hydration shell of the peptides and hydrophobic effects of fluorine groups. 
Montserret et al. have shown that although the folding of amphipathic α-
helical peptides in hydrophilic SDS micellar solutions is mostly driven by 
electrostatic interactions, when hydrophobic peptides are considered, 
SDS–peptide hydrophobic interactions might be sufficiently strong to 
induce α-helical-rich structures (Montserret, 2000). The effect of 
fluorinated complexes made of polyampholyte and the sodium salt of 
perfluorododecanoic acid on Aβ was attributed to the hydrophobic and 
acidic characters of the perfluorododecanoic acid (Rocha, 2008; Saraiva, 
2010). Also, it is proposed that LVFfFD-PEG and LVfFFD-PEG have the 
necessary hydrophobicity and spatial geometry to allow the interaction 
with Aβ(1-42). LPfFFD-PEG, with one fluorine atom in the proline residue, 
was not able to prevent Aβ-Aβ interactions. Proline residues are generally 
solvent-exposed in proteins and they are considered binding motifs in 
protein-protein interaction (Kay, 2000). The fluorinated proline is 
probably inducing a conformation on the conjugate LPfFFD-PEG that 
prevents the exposure of its amino acids and their interaction with 
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residues of other peptide molecules. Comparing the LPfFFD-PEG with the 
non-fluorinated analogue, one can assume that the fluorine atom increases 
the steric hindrance of the conjugate reducing the access to the proline 
residue. On the other hand the hydrophobic interactions between LPfFFD-
PEG and Aβ are probably not strong enough when compared to the Aβ-Aβ 
interactions. Apart from the apparently reduced interaction between Aβ 
and LPfFFD-PEG, the position of fluorine atoms at the extremity of the 
conjugate and the fluorination of hydrophobic residues seem to favour the 
inhibitory effect of the sequences on Aβ amyloid fibril formation.   
 
4.3.3. Toxicity assay 
The cell toxicity of the conjugate LVFfFD-PEG was assessed using 
PBCEC cultures. After two hours of incubation of the cells with the 
fluorinated peptide conjugate, the cells were incubated with the Alamar 
Blue solution at 37°C. The results demonstrate that the LVFfFD-PEG 
conjugate is not toxic for PBCECs at concentrations lower than 2 mM. 
 
 
Figure 4.6 - Alamar Blue assay of PBCECs cultured with different 
concentrations of LVFfFD-PEG  conjugate monitored during 24 hours at 
37°C. 
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This study opens up the possibility of using fluorinated peptide-
PEG conjugates as inhibitors of the Aβ peptide aggregation. 
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 Chapter 5 
5. Design of liposomes coupled to 
monoclonal antibodies to cross the 
blood-brain barrier  
 Introduction 5.1.
Liposomes are one of the most studied vehicles to carry drugs to 
the site of action. A polymer PEG can be attached to the nanocarriers to 
reduce their immunogenicity and prolong their half-life time (Immordino, 
2006). Also, they are rapidly biodegradable, i.e. over a time frame of a few 
days, which is one important major requirement for NPs brain delivery 
systems (Wohlfart, 2012). Liposomes have further documented 
advantages as increased drug loading capacity, versatile structural 
characteristics that permit easy surface functionalization, biocompatibility 
and reduced toxicity (Markoutsa, 2011a). In addition, to improve the 
selectivity of the nanoparticles, numerous ligands can be attached to their 
surface including mAb, which are one of the most efficient ligands to 
accomplish this action. TrR has been shown to be selectively enriched at 
the brain capillary endothelium and has been demonstrated to undergo 
RMT through the BBB (Cerletti, 2000). In general, in vitro models that 
allow reliable prediction of drug and/or carrier brain penetration are very 
useful. The PBCECs constitute a well-characterized cell line, which has 
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been demonstrated to mimic the basic characteristics of the BBB 
(Markoutsa, 2011a). Also, for in vivo studies, rats represent a good model. 
This chapter describes the design, synthesis and the properties of 
functionalized liposomes with mAb for BBB endogenous receptors and 
mAb for Aβ peptide aggregates. The specific antibody type OX-26 was 
selected since it has been well described to bind cells that express the TfR 
such as the BBB cells (Schnyder, 2004). The mAb 19B8 for Aβ can be used 
to carry the immunoliposomes directly to Aβ plaque deposits.  
 
 Materials and methods 5.2.
 Liposomes 5.2.1.
All the lipids were purchased from Avanti Polar Lipids: DSPC (1,2-
distearoyl-sn-glycero-3-phosphocholine, MW 790.145), Chol (cholesterol 
ovine wool, MW 386.65), DSPE-PEG2000 (1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (ammonium 
salt), MW 2790.49), DSPE-PEG2000-mal (1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] 
(ammonium salt), MW 2941.61), DSPE-PEG2000-biot (1,2-distearoyl- sn-
glycero-3-phosphoethanolamine-N-[biotin(polyethylene glycol)-2000] 
(ammonium salt), MW 3016.78) and Liss Rhod PE (1,2-dipalmitoyl-sn-
glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) 
(ammonium salt), MW 1249.64). 
The chemical structure of the phospholipids is shown in table 5.1. 
The pegylated phospholipids have a molecular weight of approximately 
2000 Da in order to confer stability to the liposomes without significantly 
vary their size.  
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Table 5.1 - Chemical structure of the lipids used to prepared 
immunoliposomes 
Chemical Structure Names 
 
DSPC: 1,2-distearoyl-sn-
glycero-3-
phosphocholine 
 
DSPE-PEG: 1,2-dioleoyl-
sn-glycero-3-
phosphoethanolamine-
N-
[methoxy(polyethylene 
glycol)-2000] 
 
DSPE-PEG(2000) 
Maleimide: 1,2-
distearoyl-sn-glycero-3-
phosphoethanolamine-
N-
[maleimide(polyethylene 
glycol)-2000] 
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Chemical Structure Names 
 
DSPE-PEG(2000) 
Biotin: 1,2-distearoyl-
sn-glycero-3-
phosphoethanolamine-
N-[biotin(polyethylene 
glycol)-2000] 
 
Liss Rhod PE: 1,2-
dipalmitoyl-sn-glycero-
3-
phosphoethanolamine-
N-(lissamine rhodamine 
B sulfonyl) 
 
Cholesterol 
 
 
Liposomes were prepared by the classical method of the lipid film 
hydration (Lasic, 1995). DSPC, Chol, DSPE-PEG2000, DSPE-PEG2000-mal, 
DSPE-PEG2000-biot and Liss Rhod PE were dissolved in chloroform (Mw 
119.38, Sigma-Aldrich), at the molar ratio of 52:45:3:0.015:0.015:0.01, and 
the solvent was evaporated to dryness with a nitrogen stream in a rotary 
evaporator. The resultant dried lipid film was dispersed in PBS buffer, pH 
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7.4 (phosphate buffered saline, 10 mM phosphate buffer, 2.7 mM 
potassium chloride and 137 mM sodium chloride, Sigma-Aldrich) with a 
final lipid concentration of 0. 8 mM and the mixture was vortexed to yield 
MLVs. In order to obtain LUVs, the suspension was subjected to 10 
freezing/unfreezing cycles, followed by extrusion 13 times through a 
polycarbonate filter with a pore diameter of 200 nm, 100 nm and finally 
50 nm at RT. 
 
 Conjugation of antibodies 5.2.2.
The mAb for transferrin BBB receptors, OX-26 mAb, was obtained 
from AbD Serotec and the mAb for amyloid beta peptide, 19B8, was 
purchased from Abcam.  
Covalent coupling methods for attaching the antibodies at the PEG 
terminus by using functionalized PEG with a chemically reactive end-
group were applied. Two activated PEG molecules, the PEG-maleimide 
(thiol reactive) and a PEG-biotin (biotin–streptavidin), were used as two 
different antibodies were coupled to the systems. For the maleimide-mAb 
conjugation, the target was activated by a twenty times molar excess of 
Traut’s reagent (2-iminothiolane hydrochloride, MW 137.73, Sigma-
Aldrich). A drop of EDTA (ethylenediaminetetraacetic acid, MW 292.40, 
Sigma-Aldrich) 0.28 M was added to prevent metal catalyzed oxidation of 
sulfhydryl groups (Hermanson, 1996). To remove the unreacted EDTA/2-
iminothiolane complexes, size exclusion chromatography was applied 
using a Sephadex column PD-Mini Trap G25 (GE Healthcare) (Markoutsa, 
2012).  
The second mAb was firstly coupled to a biotin molecule using the 
EZ-Link micro sulfo NHS-LC-biotin (Thermo Scientific) kit. To link this 
mAb to the functionalized PEG-biotin, a molar ratio of 1:1 of streptavidin 
  
 
108 Chapter 5 
 
(from Streptomyces avidinii, Sigma-Aldrich) was previously added to the 
liposomes. 
Both antibodies were added to the liposomes at a molar ratio of 1:1 
between antibodies and functionalized PEG. Each antibody was incubated 
at RT for 1 hour and then at 4 °C during 8 hours. 
The affinity of the immunoliposomes for transferrin or Aβ was 
analyzed by the enzyme-linked immunosorbent assay (ELISA). The surface 
of a 96 well plate (flat-bottom Nunc MaxiSorp®) was coated with TfR 
(Abcam) and Aβ (β-Amyloid (1-42) Human, purity >95%, GenScript) 
during 1 hour at 37 °C. After the block with the BSA (bovine serum 
albumin, ~ 66 kDa) the immunoliposomes were added to each well and a 
period of incubation followed. After washing, the secondary antibody 
(Goat anti-Mouse IgG (H+L), Thermo Scientific-Pierce Antibodies), 
conjugated with peroxidase, reacted during 45 minutes at RT. To reveal 
the reaction, a citrate solution was used with citric acid (MW 210.14, 
Sigma-Aldrich), ABTS (2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic 
acid) diammonium salt, MW 548.68, Sigma Aldrich) and H2O2 (hydrogen 
peroxide solution, MW 34.02, Sigma Aldrich). The intensity of the signal 
was measured by absorbance spectrometry at 405 nm using a Biotek 
Synergy 2 spectrometer. Liposomes without mAb were used as control.  
 
 Stability studies 5.2.3.
The stability of the immunoliposomes was analyzed through the 
size and zeta potential variation. The size of the immunoliposomes was 
measured by dynamic light scattering (DLS) technique at RT. Zeta 
potential was also measured for the same samples by the laser doppler 
velocimetry method. The measurements were performed in a Malvern 
Zetasizer instrument. 
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5.2.3.1. Zeta potential 
The electric potential at the shear plane is called zeta potential. The 
net charge density on a particle in contact with an aqueous solution gives 
rise to an electrical double layer, comprised of a fixed layer which includes 
strongly adsorbed counterions at specific sites on the surface and an outer, 
diffuse layer composed of counterions whose distribution is determined 
by a balance of electrostatic forces and random thermal motion. In the 
presence of an applied electric field, each particle (and strongly adsorbed 
ions) moves with respect to the medium. Between the two phases there is 
a shear plane, i.e. the hypothetical boundary between the particle with its 
ion atmosphere and the surrounding medium.  
The zeta potential of dispersed colloidal particles can be measured 
by electrophoresis. The electric force causes the particle to move in 
relation to a stationary liquid at a constant velocity. The ratio of the 
velocity to the electric field   is the electrophoretic mobility,   . 
The mobility is converted into zeta potential,   , using the 
Smoluchowski equation 5.1: 
        
(5.1) 
 
where   is the viscosity of the solution and   is the permittivity of the 
solution.  
 
5.2.3.2. Dynamic light scattering 
DLS, also referred to as quasi-elastic light scattering, enables the 
determination of particle size and size distribution in dispersions. The 
method is based on the fluctuations in the intensity of light scattered by a 
 =  
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𝐷 =  
𝛤
𝑞2
 
𝑞 =  
4𝑛𝜋
𝜆
 𝑠𝑖𝑛
𝜃
2
 
small volume of a solution in the microsecond time range which are 
directly related to the Brownian motion of the solute (Berne, 1976). 
Submicrometer size particles in suspension exhibit significant random 
motion because of collisions with the molecules of the surrounding liquid 
medium (Brownian motion). As a result, when light irradiates a colloidal 
dispersion, the phases of the scattered waves fluctuate randomly in time. 
The scattered light intensities from individual particles interfere with each 
other, and hence the net intensity of the scattered light fluctuates 
randomly in time. The time dependence of the intensity fluctuations, 
calculated from the autocorrelation function of the scattered intensity, can 
be related to the diffusion coefficient of the particles. For a monodisperse 
system, the normalized autocorrelation function,     , is an exponential 
decay, 
 
                𝛤                 (5.2) 
 
where     is the decay time of the autocorrelation function, 𝛤 is the decay 
constant, which is related to the diffusion coefficient 𝐷 by 
 
     (5.3) 
 
where 𝑞 is the scattering wave vector, which depends on the wavelength 
of the light source, 𝜆, the solvent refractive index, 𝑛, and the angle of 
detection, 𝜃. 
 
(5.4) 
 
The hydrodynamic averaged intensity radius of the particles,   , 
can be calculated from the diffusion coefficient 𝐷, using the Stokes-
Einstein relation  
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 𝐻 =  
𝑘𝐵𝑇
6𝜋 𝐷
 
 
(5.5) 
 
where 𝑘  is the Boltzmann constant, 𝑇 the absolute temperature and   is 
the viscosity of the medium. This relation is the basis of the particle size 
determination by dynamic light scattering, but it is valid only for 
monodisperse particles. 
 
 Uptake assays 5.2.4.
PBCECs were incubated in Plating-Medium (Earls Medium 199 
supplemented with L-Glutamine (0.7mM),  penicillin/streptomycin (1%), 
gentamicin (1%) and new-born calf serum, all the compounds are 
purchased at Biochrom) in a 96 well plate (Corning) previously coated 
with Collagen G (Biochrom). After 48 hours incubation at 37 °C, the culture 
medium was replaced. Normally, apparent confluence of the monolayers 
was reached after 4 days (approximately 6-8 x104 cells per well). At day 4 
the medium was replaced by a solution of KRB (composed by NaCl 
(sodium chloride p. A., Mw 58.44, AppliChem), KCl (potassium chloride, 
Mw 74.56, AppliChem), H2KO4P (potassium dihydrogen phosphate p.A., 
Mw 136.09, AppliChem), HEPES (hepes puffedran ≥ 99.5%, p.A., Mw 
238.31, ROTH), D-Glucose (D(+)-glucose anhydrous for biochemistry, Mw 
180.16, MERCK), MgCl2.6H2O (magnesium chloride hexahydrate p.A., Mw 
203.30, AppliChem) and CaCl2.2H2O (calcium chloride dehydrate p.A., Mw 
147.02, AppliChem)) in the presence of different liposomes concentration. 
The liposomes were incubated with the cells for 2 hours. After 
removal of the liposome suspension by aspiration, the cells were rinsed 
three times with medium at 4 °C, then washed with an acid buffer pH 3 (26 
mM C6H2Na3O7.2H2O (sodium citrate, Mw 294.10, Sigma), 9.2 mM 
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C6H8O7.H2O (citric acid monohydrated, Mw 210.14, Grussing), 90.1 mM 
NaCl and 30 mM KCl) for 5 minutes followed by washing with KRB at 4 °C. 
The supernatant was discarded and the cells were lysed with a 1% triton 
solution for one hour at 65 °C. Fluorescence was detected with a 
Fluoroskan Ascent (Labsystems). 
 
 in vivo assays 5.2.5.
Animal studies were performed with male Wistar rats (body weight 
200 g). Animals were maintained under standard conditions and were 
allowed access to food (V1534-000 R/M-H, Ssniff, Soest, FRG) and water in 
agreement with animal protection standards. All animal experiments were 
permitted by and followed the guidelines of the local authorities 
(Regierungsprasidium Karlsruhe, Germany). The nanoparticles were 
suspended in PBS to a final concentration of 1.25 mg/mL and 0.8 mL of the 
solution was administered into the tail vein. After 2 h, 4 h and 6 h the 
animals were killed by cervical dislocation and the brains were removed 
and further studied after cryosection. Usually, 2 animals were used for 
each time point. Three animals received PBS to use as a control. Brain 
tissue was cut on a cryostat CM 3050 Leica, Bensheim, FRG) and the tissue 
slices were thaw-mounted onto surface treated glass slides (Superfrost 
plus, Fisher, Pittsburgh, PA, USA). Brain slices were analyzed by confocal 
laser scanning microscopy (CLSM) with a TCS SP5 II (Leica Microsystems, 
Germany). 
5.2.5.1. Confocal Laser Scanning Microscopy 
CLSM is a microscopy technique for obtaining high-resolution 
optical images of serial optical sections of the materials. 
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The analysis of only a single focal plane of the specimen at a time is 
possible because of a pinhole placed in front of the detector, which filters 
the reflected light that comes from the specimen. The pinhole has a rather 
narrow aperture, so only the light from the microscope focal plane is able 
to pass through it, and consequently hit the detector and be imaged. The 
detector images a single point at a time. The light that comes either from 
above or below the focal plane is physically blocked by the pinhole. This 
enables the in-depth analysis of thick specimens (Sheppard, 1997). 
The light source consists of a laser beam, directed towards an 
objective which focuses this light to a single point in a given focal plane of 
the specimen. Two galvanometric scanners deflect the laser beam in the X 
and Y directions, thus enabling the line-by-line scanning of the specimen. 
The microscope stage is moved up and down by a computer-controlled 
fine-step motor, allowing the focal plane to be selected.  
When the light hits the specimen, it excites fluorescence, and this 
radiation is collected by the objective, and directed towards the detector 
through a dichroic beam splitter. The intensity of that fluorescent light is 
directly proportional to the intensity of the resulting pixel. 
The use of a laser beam as a source of light and a photomultiplier as a 
detector allows one to perform a point wise illumination of the specimen, 
and to obtain a significant output signal even if the amount of light in the 
final image is reduced due to the confocal filtering. 
 
 Peptide encapsulation 5.2.6.
The β-sheet breaker peptide LPFFD, conjugated with a fluorophore 
(5-FAM-(Leu)-(Pro)-(Phe)-(Phe)-(Asp)), purity 98.9%, MW 994.04, 
GenScript) was encapsulated in the immunoliposomes. For an efficient 
peptide encapsulation, dried lipid film was hydrated with an aqueous 
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solution containing the peptide with molar ratios of 16:1 and 10:1 
(phospholipids:peptide). To study the efficiency of encapsulation, a 
Sephadex column PD-Midi Trap G25 (GE Healthcare) was used to separate 
the encapsulated peptide from the free molecules. After this separation, 
liposomes were burst with water:ethanol in a 25:75 (v/v) proportion and 
their fluorescence was measured (Spectrofluorometer FP-6500). 
The encapsulation efficiency was calculated based on equation 5.6. 
 
                              
                      
                           
          (5.6) 
 
 Phase transition studies 5.2.7.
Lipid phase transitions in biological media are correlated to 
discontinuities or anomalies in macroscopic physical properties such as 
the stability, fluidity or permeability of membranes which are closely 
dependent on their phase transition temperature (Mouritsen, 1995). A 
liposome becomes highly permeable near the gel to crystalline phase 
transition temperature of its membrane (Papahadjopoulos, 1973). This 
shape alteration induced by the phase transition was correlated with the 
refraction and absorption coefficients of the aqueous dispersion. In light 
scattering terms, the measured count rate (average number of photons 
detected per second) can change for any of the following reasons: 
alterations in the structure (i.e. refractive index) of the particle membrane, 
alterations in the size of the particles and alterations in the concentration 
of the particles (Michel, 2006). 
The phase transition temperature of the liposomes was studied by 
the analysis of the mean count rate (Michel, 2006) with a BI-MAS DLS 
instrument (Brookhaven 189 Instruments, USA). The study was done in a 
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temperature range between (20.0 ± 0.1)°C and (70.0 ± 0.1)°C, with 
intervals of 1.0 ± 0.1°C and with an equilibration period of 2 minutes. At 
each temperature 4 runs of 2 min were performed. In order to use the 
photon count rate within the recommended range (250-500 kcps), 
liposomes were diluted, so as to have a final sample concentration of 500 
µM and the liposomes loaded with peptide were prepared with a molar 
ratio of 16:1 (phospholipid:peptide). 
  
 Release studies 5.2.8.
Drug release experiments of the peptide encapsulated into the 
LUVs were run using a dialysis membrane (Float-A-Lyzer G2, CE, 100 KDa, 
SpectrumLabs). The membranes were washed in ultrapure water for 12 
hours before being used and equilibrated with buffer 1 hour before the 
dialysis with PBS buffer as the receiving phase. A volume of 2 mL from the 
immunoliposomes suspension was added to the membrane and the 
outside space was filled with 6 mL of buffer. The dialysis membrane was 
kept in continuous stirring at 200 rpm at 4 °C simulating the production of 
the carriers and at 37 °C simulating the physiological temperature. At 
different time intervals, samples were collected from the outside medium 
and the same volume of fresh release medium was added. The amount of 
released peptide was determined by fluorescence (Spectrofluorometer FP-
6500).  The percentage of peptide released at each time is then calculated 
from the Equation 5.7. 
 
                                       
          
              
          (5.7) 
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where the [peptide]t is the peptide concentration at each measuring time 
and [peptide]total is the concentration of the encapsulated peptide at initial 
time. 
 
 Results and Discussion 5.3.
 Conjugation of antibodies 5.3.1.
During these experiments four types of liposomes were developed. 
As a control, pegylated liposomes without mAb were prepared. The first 
study consisted in coupling just one type of mAb (OX-26) to the surface of 
the liposomes. To test the influence of the distance between the liposome 
surface and the mAb, two other systems were designed. One of them has 
the OX-26 linked to biotin-streptavidin, which makes it more available. 
The other system has the same mAb but connected to a maleimide group, 
which could decrease the distance between the mAb and the liposome 
surface, due to the different lengths of the ligands, and thus make the mAb 
more hidden (Figure 5.1). 
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Figure 5. 1 - Schematic representation of the developed systems: A) 
pegylated liposomes; B) pegylated liposomes coupled with OX-26 through 
PEG-maleimide; C) pegylated liposomes coupled with two different mAb, 
OX-26 through PEG-maleimide and 19B8 through PEG-Biotin; and D) 
pegylated liposomes coupled with two different mAb, OX-26 through PEG-
Biotin and 19B8 through PEG-maleimide. 
 
The binding of the mAb to the nanocarriers was determined by 
ELISA.  Significantly higher absorbance at 405 nm was observed with 
immunoliposomes. The control used in these assays exhibited significantly 
lower absorbance (0.27±0.03) when compared with the liposomes 
conjugated to the mAb OX-26 (0.68±0.04). Also, both pegylated liposomes 
coupled with two different mAb by different methods, had a positive 
reaction for OX-26 (0.70±0.03) and for 19B8 (0.69±0.05). Therefore, the 
bioactivity of the mAb used was validated by this assay: OX-26 mAb 
maintains its reactivity for transferrin receptor and 19B8 mAb for Aβ 
peptide monomers.  It was also verified that 19B8 mAb has affinity for 
oligomers (considered to be the most toxic species of Aβ peptide). 
The number of mAb conjugated on each liposome was further 
calculated based on the assumption that liposomes with a diameter of 100 
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nm contain about 100000 molecules of phospholipids (Hansen, 1995). As 
the prepared liposomes present a hydrodynamic diameter around 95 nm, 
the number of phospholipids estimated was 95000. Assuming this 
number, the liposomes that have just one type of antibody it will have 
approximately 15 OX-26 mAb molecules. In the case of the  
immunoliposomes containing the two mAb, they have a totally of about 30 
mAb molecules (15 of the 19B8 mAb and 15 of OX-26 mAb). Interestingly, 
this optimal number of 30 mAb per liposome was also observed in 
experiments where pulmonary endothelial cells were targeted in vivo 
using mAb conjugated liposomes (Maruyama, 1995; Schnyder, 2005).  
It has been proved previously that thiolation of mAb does not 
interfere with their binding site (Pardridge, 1995). Though maleimide 
group when in contact with water could be hydrolyzed, so it is essential to 
add the antibodies immediately after the liposome preparation.  
 
 Stability studies 5.3.2.
The liposome size was determined after each step of preparation. 
The mean diameter and vesicle size distribution were used as an 
indication of sample aggregation and stability. Carriers were prepared by 
repeated extrusion processes through polycarbonate filter membranes 
with a final pore size of 50 nm. By this method, an average diameter of the 
liposomes was obtained with a sharp distribution of dimension (table 5.2).  
For the immunoliposomes with one mAb type, the size increased of 
about 15 nm, which is the approximately diameter of the globular mAb 
(Dammer, 1996). This result also confirms an efficient conjugation. In the 
case of the two-mAb coated immunoliposomes, the same increase was 
observed with the addition of the first mAb. The second step in the 
preparation of this system was the addition of streptavidin that does not 
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change significantly the NPs size.  The absence of a fluctuation in the 
dimension could be explained by the smaller size of streptavidin molecule 
comparatively to the mAb that was added first to the liposome and by its 
conjugation to biotin (Figure 5.1). In the last step of this procedure the 
second mAb causes also a rise of about 15 nm (Table 5.2).  
 
Table 5.2 - Mean diameter, polydispersity index (PI) and zeta potential of 
the immunoliposomes at each step of their preparation. 
Particle 
Mean diameter 
(nm) 
PI 
Zeta Potential 
(mV) 
Pegylated liposomes 95.2 ± 0.8 0.07 ± 0.01 0.7 ± 0.4 
Pegylated liposomes with 
one mAb 
107 ± 4 0.19 ± 0.01 -2.0 ± 0.3 
Pegylated liposomes with 
one mAb and streptavidin 
106 ± 4 0.17 ± 0.01 -2.7 ± 0.1 
Pegylated liposomes with 
two mAb 
114 ± 1 0.20 ± 0.01 -2.6 ± 0.2 
 
In order to study the stability of the liposomes over time, their size 
was measured during 2 months. Over this time, there were no significant 
variations on these parameters, which indicate that the liposomes are 
stable. Changes in the size and zeta potential values means that the 
structures of liposomes rearrange, i.e., the structures will be different from 
the initial ones and the liposomes will lose their stability (Mason, 2003). It 
is very important to certify that the vesicles are not aggregated, since the 
size and stability of immunoliposomes are critical for their cell 
internalization. Besides, aggregation could result in a decrease of the 
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antibody density on the vesicles. Nonetheless, even with the highest 
antibody density, the vesicle diameters are <200 nm, which is the size 
required for targeting (Markoutsa, 2011a).  
The addition of the mAb to the liposomes does not significantly 
affect their zeta potential. Although a smaller variation to a negative value 
was verified due to the negative nature of the immunoglobulins.  
 
 Uptake assay 5.3.3.
Current most common method for modeling the BBB penetration 
includes the use of cultured endothelial cells in vitro. In this study the 
PBCECs were used to mimic the endogenous microvascular endothelial 
cells due to their expression of tight junctions proteins (Brown, 2007). The 
in vitro cell uptake index of liposomes was studied with 2 h incubation 
time at 37 °C. The relative uptake efficiency was calculated by dividing the 
uptake amount of NPs in contact with the cells during the 2 hours 
incubation, by the initial concentration of liposomes.  
As shown in figure 5.2, when the amount of immunoliposomes 
incubated with cells increases, the vesicle uptake percentage decreases, 
which indicates a concentration-dependent mechanism. Control vesicle 
(pegylated liposomes with no antibody attached) uptake by PBCECs is 
substantially lower (2.7±0.2% at 160 μM and 2.3±1.6% at 60 μM) 
comparatively to the uptake of liposomes B (4.0±0.8% at 160 μM and 
6.4±2.4% at 60 μM)  and D (7.3±0.7% at 160 μM and 15.4±1.4% at 60 μM), 
which confirms that OX-26 increases the liposome uptake by the 
endothelial cells from BBB. The presence of the antibody at the liposome 
surface allows, its uptake by receptor-mediated transport which is more 
selective and efficient than the simple diffusion used by the control 
liposomes. This phenomenon is well observed for the concentration of 60 
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µM. A difference between the three types of carriers at 200 µM is not 
verified. These results suggest a saturation in the cells when in contact 
with the liposomes at higher concentrations, since a similar uptake was 
verified for liposomes A, B and D (3.1±0.8%, 3.9±0.6% and 4.0±1.2%, 
respectively).  
Additionally, the liposomes D have a higher uptake than the 
liposomes B for the two lowest concentrations. This difference could be 
explained by the higher availability of OX-26 in the liposomes D, due to the 
presence of a streptavidin molecule that can work as a spacer in addition 
to its ligand function. Furthermore, it is known that an increase in the 
surface density of liposomes will imply a higher uptake (Markoutsa, 
2011a). 
In contrast with liposomes D, the uptake of liposomes C was very 
low (0.6±0.4% at 200 μM, 0.5±0.2% at 160 μM and 0.4±0.3% at 60 μM). 
The difference in the design of these liposomes is based on the different 
methods of conjugation used to couple the two types of antibodies. OX-26 
is more available to the transferrin receptors when linked by biotin-
streptavidin method.  In the liposomes C the anti-transferrin receptor 
antibodies were bound through the thiol-maleimide conjugation. The 
addition of molecules of streptavidin and a second antibody to these 
liposomes could prevent the binding of OX-26 to its ligand and interfere 
with their uptake by receptor-mediated transport. Although their 
transport by simple diffusion is also not verified like in liposomes A. This 
may be explained by the negative nature of the liposomes C in contrast 
liposomes A are zwitterionic. A negative repulsion between the cellular 
membrane and liposomes C could be occurring.  
These results demonstrated that immunoliposomes with the two 
mAb OX-26 and 19B8 can be an effective carrier for brain drug delivery, 
since they are internalized by BBB model cells. 
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Figure 5.2 - Concentration-dependent uptake of liposomes by PBCECs. Data 
are the mean of three assays and respectively standard deviation. The 
liposomes used are: A) pegylated liposomes; B) pegylated liposomes 
coupled with OX-26 through PEG-maleimide; C) pegylated liposomes 
coupled with two different mAb, OX-26 through PEG-maleimide and 19B8 
through PEG-Biotin; and D) pegylated liposomes coupled with two different 
mAb, OX-26 through PEG-Biotin and 19B8 through PEG-maleimide. 
 
 in vivo assays 5.3.4.
To evaluate the capability of the liposomes to permeate the BBB, 
brain slices of rats treated with the immunoliposomes were observed by 
CLSM. Figure 5.3 shows the cryosections of the rats’ brains. All of the 
sections were performed in the cortex of the brains. The nucleus were 
marked with 4',6-diamidino-2-phenylindole (DAPI). Distinct signals can be 
seen in the blue channel images (Figure 5.3), which coincide with the 
pattern of the stained nucleus of cells that can be clearly observed.  
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The first row shows the brain section of a rat that was treated only 
with PBS buffer. These sections serve as a negative control to ensure that 
the anesthesia and sacrifice do not leave any red fluorescing traces, which 
could be mistaken as fluorescing liposomes. 
Further, brains of the rats injected with liposomes were also 
observed. The fluorescence from the rhodamine fluorophore present in 
the liposomes is clearly visible in all the section. The images from the brain 
with liposomes coupled with mAb show, however, higher fluorescence 
than the images of liposomes not coated with mAb. These results show 
higher uptake when the liposomes are coupled with mAb, and are in 
agreement with the results obtained in the in vitro assays. 
The present study suggests that the circulation time that is 
reported herein (2 hours) is sufficiently long enough to detect BBB 
permeation and the concentration is maintained constant during 6 hours. 
Thus, it can be concluded that the particles are located in the brain 
tissue confirming the resistance of the liposomes to the immune system. 
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Figure 5.3 - Cryosections of the rat brains after administration of 
immunoliposomes. The top image shows the brain section without prior 
application of liposomes (only PBS buffer). Cell nucleus is labeled with 
DAPI. The scale bars represent 30 μm. 
 
  
 
Chapter 5 125 
 
 Peptide encapsulation 5.3.5.
The peptide LPFFD binds to Aβ peptide and blocks the interaction 
between monomers and oligomers inhibiting the formation of fibrils. 
Despite this therapeutic effect, the peptide is rapidly degraded by 
enzymes. To circumvent this problem, the peptide was encapsulated in the 
liposomes described above. 
The encapsulation efficiency was not significantly different 
between two different peptide concentrations. For a molar ratio of 16:1 
(peptide:lipid; final peptide concentration of 50 µM) 93±1% of peptide 
was encapsulated. Similarly, the encapsulation efficiency in liposomes 
with a ratio of 10:1 (peptide concentration of 75 µM) was 92.5±0.1%. As 
these values are identical, a ratio of 16:1 was used in the follow 
experiments. 
 
 Phase transition studies 5.3.6.
The evaluation of the main phase transition temperature (Tm) of 
the liposomes and the effect of the peptide loading were based on the 
change of the mean count rate. Discontinuity in the mean count rate, as the 
temperature is altered corresponds to a change in the optical properties of 
the material studied, arising from a transition from an initial state to 
another (Michel, 2006). The main phase transition and cooperativity (B) 
were determined, by adjusting a non-linear curve fit to the obtained 
sigmoidal profile, as elsewhere described (Pinheiro, 2013a; Pinheiro, 
2013b). 
The mean count rate dependence with temperature for the 
liposomes with the peptide encapsulated is shown in Figure 5.4.  
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Figure 5.4 - Average count rate of liposomes loaded with the peptide (16:1) 
as a function of temperature. Continuous line is the best-fit curve. 
 
In Table 5.3 the obtained values for the biophysical parameters are 
depicted: Tm and B of liposomes in the absence and in the presence of the 
peptide.  
 
Table 5.3 - Values of main phase transition temperature (Tm) and 
cooperativity (B) obtained for liposomes (500 µM, pH 7.4) in the absence 
and in the presence of peptide (16:1). 
 Tm (°C) Cooperativity - B 
Liposomes 51±1 579±99 
Liposomes with peptide 49.6±0.1 1105±64 
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The analysis of Table 5.3 reveals that the Tm is slightly reduced by 
the presence of the peptide and the cooperativity (B) is increased. These 
two results point to a location of the peptide closer to the head group 
region (Grancelli, 2002). 
 
 Release studies 5.3.7.
The size, solubility, composition and biodegradation of the 
nanoparticle matrix are the main factors that affect the release rate of a 
drug from nanocarriers (Kumari, 2010). Besides, a time compromise in the 
drug release profile is needed, since if the peptide-loaded liposomes 
present a too high stability, the drug liberation will not occur when the 
systems reach the active site, and if the drug is not well entrapped, it can 
lead to premature and not favorable peptide release.  
The dialysis method was used to evaluate the release profile of 
LPFFD when free and encapsulated in liposomes. These release 
experiments were carried out in PBS (pH 7.4) at 4 °C and at 37 °C. 
Release experiments provide a guidance to predict the possible 
release profile of the drug when in the designed drug carriers. The in vitro 
peptide release profile loaded in liposomes showed a regular pattern with 
a continuous burst release of the drug. As shown in figure 5.5, at 37 °C, in 
the first 12 h the 5-FAM-LPFFD was released from the carriers in a 
percentage of approximately 60%.  After 22 h, the release of the peptide 
reached a percentage of cumulative release of around 80%.  
In order to evaluate if the immunoliposomes preparation process 
influences the drug release, a study at 4 °C during 8 hours (that are the 
conjugation conditions) was performed. This conditions correspond to the 
ones necessary for an efficiently conjugation between mAb and liposomes. 
As seen in the figure 5.5, after 8 h under continuous agitation, about 7% of 
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peptide was released from the liposomes. Such results indicate that during 
the carriers’ production the percentage of drug lost is very low which 
makes them a good vehicle to transport LPFFD, since its liberation is 
favored at 37 °C (physiological temperature). 
 
 
 
Figure 5.5 - The in vitro release of 5-FAM-LPFFD from liposomes under PBS 
buffer, pH 7.4, at 4°C and 37°C. 
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Zhang et al. showed that anionic charged immunoliposomes 
(composed by 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine, 
didodecyldimethylammonium bromide, 
distearoylphosphatidylethanolamine-PEG2000) targeted with either the OX-
26 mAb or the mouse IgG2a antibody are transported intact across the 
BBB (Zhang, 2003). In another study, Cerletti et al. developed an OX-26 
immunoliposome (composed of distearoylphosphatidylcholine 
cholesterol, distearoylphosphatidylethanolamine-PEG2000) and performed 
in vitro studies using immortalized rat brain capillary endothelial RBE4 
cells. Liposomes with the specific antibody were taken up by the cells, and 
were concentrated in distinct intracellular compartments such as 
endosomes or lysosomes. During prolonged incubation times, however, 
endosomal release of the liposomal cargo into the cytosolic compartment 
can be observed (Cerletti, 2000; Markoutsa, 2011b; Roux, 2005). Shi et al. 
studied the mechanisms of interaction between the BBB and liposomes 
coupled with OX-26 mAb. According to the authors, pegylated 
immunoliposomes (1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine, 
didodecyldimethylammonium bromide, 
distearoylphosphatidylethanolamine-PEG2000) first undergo RMT across 
the BBB in vivo, owing to expression of the TfR at the BBB surface 
(Huwyler, 1998), and then undergo receptor-mediated endocytosis into 
neurons within the brain, owing to the expression of the TfR on the 
neuronal plasma membrane (Mash, 1990). The BBB TfR is a bidirectional 
transcytosis system (Zhang, 2001), and mediates the transport of the 
system through the endothelial barrier into the brain interstitial space. 
The phospholipids forming the liposome fuse with the intracellular 
endosomal membrane subsequent to endocytosis and release the drug 
into the cytosol of the target cell (Mok, 1999; Shi, 2001). 
Also, liposomes (composed by 1-palmitoyl-2-oleoyl-sn-glycerol-3-
phosphocholine, dimethyldioctadecylammonium bromide, 
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distearoylphosphatidylethanolamine-PEG2000) coupled to a mAb to the 
mouse TfR, to target the BBB and with a second mAb against the human 
insulin receptor, to target intracranial human U87 glioma showed 
promising results (Boado, 2011; Zhang, 2004).  
Liposomes functionalized with two types of antibodies are 
promising systems for brain drug delivery because they are capable of 
crossing the BBB and recognize the site of action.  
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Chapter 6 
6. Concluding remarks 
The reason why Aβ peptide forms amyloid fibrils in vivo is still not 
understood. Studies in vitro may provide important insights into the 
aggregation process of the peptide. However, the fast aggregation kinetics 
and the different aggregation stages of peptide samples contribute to the 
lack of uniform and concordant results. The use of surfactants may 
contribute to a better understanding of the peptide aggregation and above 
all may allow the study of the fibril formation at conditions that can easily 
be reproduced. 
When Aβ peptide is in solutions of negatively charged SDS micelles 
and positively charged CTAC micelles, only small aggregates are observed, 
demonstrating the inhibition of Aβ fibrillogenesis. The same results are 
obtained in the presence of salt ions. But if SDS concentrations are below 
the critical micelle concentration (CMC), the monomers promote the 
peptide aggregation. These results indicate that charged surfactants 
interact with the peptide by electrostatic interactions and induce the 
exposure of the peptide hydrophobic parts promoting hydrophobic 
interactions between the Aβ monomers. The micelles also interact with 
the Aβ monomers by electrostatic interactions, but they surround the 
peptide and consequently induce an electrostatic repulsion between the 
complex peptide-micelle favoring a non-aggregated state. Notably, vesicles 
of negatively charged surfactants have a concentration-dependence effect 
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on Aβ(1-42) structure. The increase of surfactant concentration slows down 
the fibril formation. 
The nonionic surfactant promotes the peptide aggregation below 
and above the CMC in Hepes and PBS buffer solution. The presence of 
hydrophobic surfactant monomers in solution may favor the hydrophobic 
interactions. On the other hand, when the nonionic surfactant is above the 
CMC and micelles are present in solution they act as inert bodies that work 
as nuclei of aggregation.  
In the second part of the work beta-sheet breaker peptides were 
used as model molecules to study the effect of fluorination on the Aβ 
aggregation. Therefore, sequences that play an important role on Aβ 
amyloid fibril formation were modified with fluorine atoms. The results 
show that fluorination of hydrophobic amino acids such as valine or 
phenylalanine on sequences that interfere with Aβ amyloid fibril 
formation induce a significant delay on the peptide aggregation. This effect 
is likely a result of the interaction between the fluorinated amino acids 
and the hydrophobic residues of Aβ, which is strong enough to prevent the 
contact between Aβ molecules and thus to prevent the peptide 
aggregation. The fluorination of other amino acids or the modification of 
the fluorinated sequences with hydrophilic residues at different positions 
will contribute to better understand the interaction between Aβ and 
fluorinated peptides.          
A novel brain drug delivery system is also proposed to delivery 
drugs to brain areas affected by amyloid deposits. Liposomes were 
functionalized with two types of antibodies, the OX-26, a well-known 
blood-brain barrier targeting molecule, and the 19B8, an antibody capable 
of recognizing the amyloid beta peptide. To access the use of these 
liposomes as future drug delivery systems, stability studies were 
performed and the results showed that the carriers are stable for a 
minimum period of two months. The uptake of the liposomes by porcine 
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brain capillary endothelial cells was concentration dependent, and 
liposomes with the antibody anti-transferrin receptor OX-26 were 
significantly better internalized than non-functionalized systems. 
Moreover, the results provide evidence that biotin-streptavidin method 
could be preferable to link the OX-26 over the covalent coupling method in 
the immunoliposomes containing two different antibodies. An increase of 
13% in the uptake of liposomes was observed when both antibodies are 
present, when compared with common pegylated liposomes. The in vivo 
assays show that the nanocarriers tested can evade the immune system 
cells reaching the brain in large quantities. Thus, the modified liposomes 
could be a promising carrier for delivering therapeutic drugs to the central 
nervous system (CNS). The system could provide high encapsulation 
efficiencies (93%) of beta-sheet breaker peptides and also showed a 
sustained drug release. A significantly more effective brain delivery by 
biodegradable liposomes will allow the drug to reach the brain at 
sufficient doses, leading to a significantly improvement of the treatment 
strategies of Alzheimer´s disease. 
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1. List of Abbreviations 
A Amplitude 
Aβ Amyloid-beta 
a.a. Amino acids 
AD Alzheimer's disease 
ApoE Apolipoprotein E 
APP Amyloid precursor protein 
ATP Adenosine triphosphate 
ATR Attenuated total reflectance 
AuNPs Gold nanoparticles 
BACE1 β-site amyloid precursor protein cleaving enzyme 1 
BBB Blood-brain barrier 
BSA Bovine serum albumin 
CLM Crystallization-like model 
CLSM Confocal laser scanning microscopy 
CMC Critical micelle concentration 
CNS Central nervous system 
CTAC Cetyltrimethylammonium chloride 
DLS Dynamic light scatering 
DMSO Dimethyl sulfoxide 
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DTGS Deuterated triglycine sulfate detector 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
F0 Baseline before aggregation 
FTIR Fourier-transform infrared 
hCMECDE Human endothelial cells 
HFIP Hexafluoro-2-propanol 
IR Insulin receptor 
κ Elongation rate constant 
KRB Krebs ringer buffer 
LDL Low density lipoprotein 
mAb Monoclonal antibody 
MALDI Matrix-assisted laser desorption/ionization 
MCT Mercury cadmium telluride detector 
MUVs Multilamellar vesicles 
MW Molecular weight 
NPs Nanoparticles 
OG Octyl β-D-glucopyranoside 
P-gp P-glycoprotein 
PBCECs Porcine brain capillary endothelial cells 
PBS Phospate buffered saline 
PEG Poly (ethylene glycol) 
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PI Polydispersity index 
RMT Receptor mediated transport 
RT Room temperature 
S0 Singlet ground electronic state 
S1 Singlet first electronic state 
S2 Singlet second electronic state 
SDS Sodium dodecyl sulfate 
SUVs Small unimellar vesicles 
t1/2 Half completion of aggregation process 
tso Half of the total fibril consumerism 
tlag Lag time 
Tm Main phase transition temperature 
TEM Transmission electron microscopy 
TFA Trifluoroacetic acid 
TfR Transferrin receptor 
ThT Thioflavin T 
TOF Time-of-flight mass spectrometer 
Traut's reagent 2-iminothiolane hydrochloride 
UV Ultraviolet 
vso Aggregation rate 
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1. List Amino Acids 
A.a. Abbreviation Polarity Charge (pH 7.4) 
Alanine  A nonpolar neutral 
Arginine  R Basic polar positive 
Asparagine  N polar neutral 
Aspartic acid D acidic polar negative 
Cysteine  C nonpolar neutral 
Glutamic acid E acidic polar negative 
Glutamine  Q polar neutral 
Glycine G nonpolar neutral 
Histidine  H Basic polar 
positive(10%) 
neutral(90%) 
Isoleucine  I nonpolar neutral 
Leucine  L nonpolar neutral 
Lysine  K Basic polar positive 
Methionine  M nonpolar neutral 
Phenylalanine  F nonpolar neutral 
Proline  P nonpolar neutral 
Serine  S polar neutral 
Threonine  T polar neutral 
Tryptophan W nonpolar neutral 
Tyrosine  Y polar neutral 
Valine  V nonpolar neutral 
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